Professional Documents
Culture Documents
Scientific American - February 2019
Scientific American - February 2019
COM/WSNWS
HOW
THE
BRAIN
READS
FACES
C ki the
Cracking h
neural code
S
PLU
GHOST FLOWERS
Resurrecting the genes of extinct plants PAGE 30
FE B R UA RY 2 0 1 9
VO LU M E 3 2 0 , N U M B E R 2
NEUROSCIENCE A N T H R O P O LO G Y
22 Face Values 46 Guardians of
Researchers have isolated the Tiger People
the brain regions that process As anthropologists debate how best
faces and cracked the code to protect uncontacted tribes, indig-
for recognizing them. enous groups in Colombia are work-
By Doris Y. Tsao ing to shield their isolated neigh-
B I O LO G Y bors from the march of modernity.
30 Ghost Flowers By Adam Piore
The genes of Hawaiian plants, P L A N E TA RY S C I E N C E
extinct for more than a century, 56 The Exoplanet Next Door
have been brought back from What Venus can teach us about
the dead. Today we can smell planets far beyond our own solar
their scents. system. By M. Darby Dyar,
By Rowan Jacobsen Suzanne E. Smrekar and
Stephen R. Kane ON THE COVE R
ENVIRONMENT
Scientists have taken major steps toward
40 Is Antarctica E C O LO G Y understanding how the brain recognizes faces—
Collapsing? 64 Re-engineering one of the great challenges of neuroscience.
Rapid glacier retreat could put the Colorado River Not only have they found sections of the cerebral
cortex that perform this function, they have
coastlines underwater sooner Can dam releases that mimic natu-
also decoded the computations that enable
than anticipated. ral flows restore the Grand Canyon the brain to distinguish any given face.
By Richard B. Alley ecosystem? By Heather Hansman Illustration by Maciej Frolow.
19 75 Anti Gravity
Producing, harvesting, identifying and recycling feces.
By Steve Mirsky
76 50, 100 & 150 Years Ago
78 Graphic Science
The hazards of space junk. By Mark Fischetti and
Jan Willem Tulp
SPECIAL REPORT
FROM
Mariette DiChristina is editor in chief of IY_[dj_ÒY7c[h_YWd$ THE EDITOR
Follow her on Twitter @mdichristina
BOARD OF ADVISERS
Leslie C. Aiello Edward W. Felten Lene Vestergaard Hau Satyajit Mayor Daniela Rus
President, Wenner-Gren Foundation Director, Center for Information Mallinckrodt Professor Senior Professor, National Center Director, Computer Science and
for Anthropological Research Technology Policy, Princeton University of Physics and of Applied Physics, for Biological Sciences, Tata Institute ÍÜZD§Ürr§Zr"DO«ÍDÜ«Íëd$»»5»
Robin E. Bell Jonathan Foley Harvard University of Fundamental Research Eugenie C. Scott
Research Professor, Lamont-Doherty Executive Director and William R. Hopi E. Hoekstra John P. Moore Chair, Advisory Council,
Earth Observatory, Columbia University and Gretchen B. Kimball Chair, Alexander Agassiz Professor Professor of Microbiology and National Center for Science Education
California Academy of Sciences of Zoology, Harvard University Immunology, Weill Medical Terry Sejnowski
Emery N. Brown
Jennifer Francis Ayana Elizabeth Johnson College of Cornell University Professor and Laboratory
Edward Hood Taplin Professor of
Medical Engineering and of Senior Scientist, Woods Hole Founder and CEO, Donna J. Nelson Head of Computational
Computational Neuroscience, M.I.T., Research Center Ocean Collective Professor of Chemistry, Neurobiology Laboratory,
and Warren M. Zapol Professor Kaigham J. Gabriel Christof Koch University of Oklahoma Salk Institute for Biological Studies
of Anesthesia, Harvard Medical School 0ÍrÒfr§ÜD§fr{êrZæÜèr'}ZrÍd President and CSO, Robert E. Palazzo Meg Urry
Charles Stark Draper Laboratory Allen Institute for Brain Science Dean, University of Alabama Israel Munson Professor of Physics
Vinton G. Cerf
Harold “Skip” Garner Morten L. Kringelbach at Birmingham College and Astronomy, Yale University
Chief Internet Evangelist, Google
Executive Director and Professor, Associate Professor and Senior of Arts and Sciences Michael E. Webber
George M. Church
Primary Care Research Network Research Fellow, The Queen’s College, Rosalind Picard Co-director, Clean Energy Incubator,
Director, Center for Computational
and Center for Bioinformatics University of Oxford 0Í«{rÒÒ«ÍD§fÍrZÜ«Íd|rZÜèr and Associate Professor,
Genetics, Harvard Medical School and Genetics, Edward Via College Computing, M.I.T. Media Lab Department of Mechanical Engineering,
Robert S. Langer
Rita Colwell of Osteopathic Medicine David H. Koch Institute Professor, Carolyn Porco University of Texas at Austin
Distinguished University Professor, Michael S. Gazzaniga Department of Chemical Leader, Cassini Imaging Science George M. Whitesides
University of Maryland College Park Director, Sage Center for the Study Engineering, M.I.T. Team, and Director, CICLOPS, Professor of Chemistry and
and Johns Hopkins Bloomberg School of Mind, University of California, Space Science Institute Chemical Biology, Harvard University
Meg Lowman
of Public Health Santa Barbara Senior Scientist and Lindsay Chair Lisa Randall Amie Wilkinson
Drew Endy Carlos Gershenson of Botany, California Academy of Professor of Physics, Professor of Mathematics,
Professor of Bioengineering, Research Professor, National Sciences, and Rachel Carson Center Harvard University University of Chicago
Stanford University Autonomous University of Mexico for Environment and Society, Ludwig Martin Rees Anton Zeilinger
Nita A. Farahany Alison Gopnik Maximilian University Munich Astronomer Royal and Professor Professor of Quantum Optics,
Professor of Law and Philosophy, Professor of Psychology and John Maeda of Cosmology and Astrophysics, Quantum Nanophysics,
Director, Duke Initiative for }DÜr0Í«{rÒÒ«Í«{0«Ò«µëd Global Head, Computational Institute of Astronomy, Quantum Information,
Science & Society, Duke University University of California, Berkeley Design + Inclusion, Automattic, Inc. University of Cambridge University of Vienna
LETTERS
editors@sciam.com
E35
"3®s
Durham’s scenario is somewhat similar ART DIRECTOR Jason Mischka SENIOR GRAPHICS EDITOR Jen Christiansen
PHOTOGRAPHY EDITOR Monica Bradley ART DIRECTOR, ONLINE Ryan Reid
to what we describe: In principle, given in- ASSOCIATE GRAPHICS EDITOR Amanda Montañez ASSISTANT PHOTO EDITOR Liz Tormes
finite time, the speed of light is no obstacle. COPY AND PRODUC TION
A time limit would be qualitatively similar SENIOR COPY EDITORS $`Dy¨
DïïD¨DjD´y¨Î3`¨y´¹COPY EDITOR Aaron Shattuck
MANAGING PRODUCTION EDITOR Richard Hunt PREPRESS AND QUALITY MANAGER Silvia De Santis
to imposing a finite size limit, equal to time
D I G I TA L
multiplied by the speed of light. TECHNICAL LEAD Nicholas Sollecito PRODUCT MANAGER Ian Kelly WEB PRODUCER Jessica Ramirez
CONTRIBUTOR S
DOWN UNDER DEVELOPMENT EDITORIAL David Biello, Lydia Denworth, W. Wayt Gibbs, Ferris Jabr, Anna Kuchment,
Robin Lloyd, Melinda Wenner Moyer, George Musser,
In “Body Balance” [Advances], Maya Mill- Christie Nicholson, John Rennie, Ricki L. Rusting
ART Edward Bell, Bryan Christie, Lawrence R. Gendron, Nick Higgins
er reports that developmental biologist
Alberto Roselló-Díez and his colleagues EDITORIAL ADMINISTRATOR Ericka Skirpan SENIOR SECRETARY Maya Harty
found that when they suppressed growth
of a limb in a mouse fetus, the surround-
ing cells communicated with the placenta, PRESIDENT
PRINT PRODUCTION
with a key role in body growth, such as the ADVERTISING PRODUCTION CONTROLLER Carl Cherebin PRODUCTION CONTROLLER Madelyn Keyes-Milch
liver, also participate in the systemic re-
sponse triggered by a local injury. They
could do so either in parallel to the placen-
ta or at subsequent (postnatal) stages once LE T TER S TO THE EDITOR
3Zr§ÜZ¡rÍZD§d®%ré?«Í0DîDd3æÜr×ððd%ré?«Íd%?®ððð®×ä«ÍrfÜ«ÍÒNÒZD¡»Z«¡
the placenta is no longer present. "rÜÜrÍÒ¡DëOrrfÜrf{«Ír§ÜD§fZDÍÜë»=rÍrÍrÜÜDÜérZD§§«ÜD§ÒérÍrDZ«§r»
«§ÜrZ«§èrÍÒDÜ«§«§§ruèÒÜIY_[dj_ÒY7c[h_YWd«§DZrO««D§f5éÜÜrÍ»
ERRATUM H O W T O C O N TA C T U S
“The Unsolvable Problem,” by Toby S. Cu- Subscriptions Reprints Permissions
bitt, David Pérez-García and Michael Wolf, For new subscriptions, renewals, gifts, To order bulk reprints of articles For permission to copy or reuse material:
payments, and changes of address: (minimum of 1,000 copies): 0rÍ¡ÒÒ«§ÒrµDÍÜ¡r§Üd3Zr§ÜZ
should have worded a mathematical state- U.S. and Canada, 800-333-1199; American, 1 New York Plaza, Suite 4600,
Reprint Department,
ment about deriving the number 1 from outside North America, 515-248-7684 or New York, NY 10004-1562; randp@SciAm.com;
3Zr§ÜZ¡rÍZD§d
ééé»3Zr§ÜZ¡rÍZD§»Z«¡ ééé»3Zr§ÜZ¡rÍZD§»Z«¡ØµrÍ¡ÒÒ«§Ò.
any whole number in this way: “If you 1 New York Plaza, Please allow three to six weeks for processing.
Submissions
take any whole number and divide it by 2 To submit article proposals, follow the
Suite 4600,
Advertising
guidelines at ééé»3Zr§ÜZ¡rÍZD§»Z«¡. New York, NY ééé»3Zr§ÜZ¡rÍZD§»Z«¡ has electronic
if it’s even or multiply it by 3 and add 1 if
Click on “Contact Us.” 10004-1562; contact information for sales representatives
it’s odd, and then repeat the process, you We cannot return and are not responsible 212-451-8415. of 3Zr§ÜZ¡rÍZD§§DÍr«§Ò«{
always eventually reach the number 1.” {«Í¡DÜrÍDÒfrèrÍrfÜ««æÍ«}Zr» For single copies of back issues: 800-333-1199. the U.S. and in other countries.
SCIENCE AGENDA
O PI NI O N A N D A N A LYS I S FR OM
SC IENTIFIC A MERIC AN ’ S B OA R D O F E D I TO R S
Call the
Midwife ...
If You Can
For better birth outcomes, the U.S.
should rethink maternity care
By the Editors
FORUM
Howard M. Fillit is founding executive director and chief C OMM E N TA RY O N S C IE N C E IN
ÒZr§Zr«}ZrÍDÜÜrîr¡rÍÊÒÍæÒZ«èrÍë«æ§fDÜ«§ T H E N E W S FR OM T H E E X P E R T S
§%ré?«ÍÜë»
New Strategy Despite the existing tests for diagnostic and prognostic bio-
markers, few patients in the U.S. have been tested with these con-
firmatory tests because of cost and access restrictions. And payers,
for Alzheimer’s including Medicare, will not cover amyloid PET scans, based on
the perception that a definitive diagnosis has little clinical value.
We need better molecular biomarkers But recent studies on the value of PET beta-amyloid brain
scans, supported by the Centers for Medicare & Medicaid Servic-
to create targeted drugs es, have shown that practicing “dementia expert” doctors mis-
By Howard M. Fillit diagnose Alzheimer’s in about 50 percent of cases and change
their management and treatment of patients nearly 70 percent of
Alzheimer’s disease is the sixth leading cause of death in the the time when this test is used. An inexpensive blood test, covered
U.S., and unlike with cancer and heart disease, we lack the tools by insurance, which can be performed in any clinical setting,
to effectively diagnose and treat it. In sharp contrast to other ill- would have a big impact on patients and their caregivers.
nesses and despite many efforts, huge expense and hundreds of Recently the FDA issued guidelines recognizing the important
clinical trials, no new treatments have been approved in the past role of biomarkers in demonstrating efficacy in clinical trials for
16 years. The emphasis has been on drugs targeting beta-amy- Alzheimer’s (especially early-stage ones). These new guidelines
loid proteins, which clump into plaques in the brains of afflicted are a major step forward for fast-tracking drugs for the disease.
people. Unfortunately, these approaches have not
yet yielded the results we hoped for.
So now it is time to target novel pathways to tack-
le this incredibly complex disease. This has been a
challenge because of the absence of affordable and
noninvasive tests based on biomarkers that doctors
can easily use in their offices. The alternatives have
been expensive and invasive spinal taps or neuro-
imaging tests that can be performed only in a hospi-
tal or freestanding radiology office. New biomarkers
are needed for specific molecular targets that can be
used to subtype patients; for predicting the likeli-
hood that they will acquire Alzheimer’s; and possibly
for providing a diagnosis even before symptoms are
noticeable, enabling prevention. That is, they could
do what currently available amyloid positron-emis-
sion tomography (PET) scans and cerebrospinal flu-
id tests do. Biomarkers can also be used to enroll pa-
tients in clinical trials directed to a specific target,
such as beta-amyloid, and to measure how the body
responds to a treatment—as was done most recently
by Biogen with its anti-beta-amyloid monoclonal an-
tibody. Ultimately biomarkers can determine which therapies We need comparable tests—preferably blood tests—to help
would be most effective for an individual. diagnose Alzheimer’s and evaluate treatments. This will aid us in
Such tools are already available for other diseases, including making clinical trials more rigorous, affordable and efficient,
diabetes, hypertension, hyperlipidemia and cancer. In heart dis- will accelerate drug development and will improve clinical care
ease, for instance, serum cholesterol levels, which are measured by providing access to accurate diagnoses. A new initiative called
after simply drawing blood with a needle stick, have long been the Diagnostics Accelerator, under the auspices of the Alzhei-
used as a biomarker to identify patients at risk. The test is afford- mer’s Drug Discovery Foundation, aims to develop novel bio-
able and generally covered by employers or health insurance pro- markers from blood and accessible fluids and tissue. Such mark-
viders, including Medicare. If blood levels are high, drugs such as ers, specifically tied to Alzheimer’s or other forms of dementia,
statins can be prescribed to lower cholesterol and with it the risk will allow us to predict more accurately which treatment and pre-
for heart disease. Doctors can also use cholesterol levels to see if vention strategies will work in at-risk populations, as we can now
a prescribed drug is working or needs an adjustment. LDL cho- do in cancer, heart disease and other diseases of aging.
lesterol is also recognized as a biomarker for heart disease risk by
JOIN T HE CONVERSAT ION ONLINE
the Food and Drug Administration, so clinical trials can show Visit 2_w²í_Ĉ¬wÞ_C² on Facebook and Twitter
that a drug lowers cholesterol and get approval for it. or send a letter to the editor: editors@sciam.com
ADVANCES
D I S PATC H E S FR OM T H E FR O N TIE R S O F S C IE N C E , T E C H N O LO GY A N D M E D I C IN E IN S ID E
ANIMAL COGNITION
Killer
Personality
Despite evolving separately,
orcas and chimpanzees
have strikingly similar
personality traits
ÇD³ąxxäD³l¦§§xßÿD§xäDþxäøßÇß䳧ā
ä§DßÇxß丳D§îāÇ߸§xäÍ
ADVANCES
B I O C H E M I S T RY ¸§äj§¸¸¦ä
¸ß
¸øßäøUäîD³`xä`¸¸³³
øß³xi`Dx³xD³lîx¸U߸³xjU¸î
Urine Trouble
¸ø³l³`¸`¸§DîxjîxDD³l`¸xxç`¸î-
³³xjÇ߸lø`xlDä³`¸î³xUßxD¦äl¸ÿ³ç
5xäî³
¸ß`Dx³x³Çxx`¸ø§l and urobilin—degraded hemoglobin that
x§Çlxîx`î`¸ø³îxß
xîäDǧxä þxäøß³xîäāx§§¸ÿ`¸§¸ßÍ5xîx`³Ôøx
xǧ¸āä§Ôøl`߸Dî¸ßDÇāî¸äxÇD-
In a disturbing trend, scam artists are ßDîxøß³xj¥øäîDäÿDîxßäǧ§xl¸³ÇDÇxß
øä³`¸xß`D§§ā丧l
D¦xøß³xî¸
¸¸§ äxÇDßDîx䳦³î¸lxßx³î`¸§¸ßäÍ5x
doctors into prescribing pain medications `¸Ç¸ø³läîx³¸ÿ³î¸DäääÇx`î߸-
äø`Däāl߸`¸l¸³xÿ``D³îx³Ux xîxßäîDîlx³î
āîxUāîxß
`¸³äøxl¸ß§§xD§§ā丧lÍ5xäā³îxî` ¸§x`ø§DßÿxîäÍ
pee lets patients pass tests intended to 5xä`x³îäîääîølxlîxþD߸øä
ensure they are not already taking opioid äøUäîD³`xä³
¸øßlxßx³î߸øÇäÍ'³x
xl`Dä¸ßlßøä¸
DUøäxÍ0Dîß`¦!ā§xj ߸øǸ
¿ććøß³xäDǧxä`Dx
߸
lßx`î¸ß¸
`§³`D§`xäîßāD³lî¸Ā`¸§¸- Çx¸Ç§xÿ¸DlUxx³¸UäxßþxlÇ߸þl³
āDîîx7³þxßäîā¸
$ääääÇÇ$xl`D§ 0DäîDÇÇ߸D`xäî¸äǸîî³
D¦xäÇx`- îxÍäx`¸³läxî¸
¿ćć`Dx
߸³l-
Center, says that “packaging materials and mens have included testing urine’s acidity þløD§ääxx¦³ÇD³xl`Djÿ¸ÿxßx
`¸³îD³xßä
¸ßä¸x¸
îxäxÇ߸lø`îäDßx and density and assessing concentration ³¸î¸UäxßþxlÍîßl`Dx
߸öćć
Ux³§x
î³îxßxäî߸¸äÚDîä¸äÇîD§Í ¸
DxîDU¸§`ÿDäîxäøUäîD³`x`D§§xl ø³¸Uäxßþxl¥¸UDÇǧ`D³îäͳlîx³D§
Hoping to address the situation, Kyle and creatinine. But some synthetic products ߸øÇ`¸³ääîxl¸
¿ćäDǧxä¸
`¸xß-
äÇD¸äî`¸§§xDøx Däÿ³lxß!Døß ³¸ÿÇDääîxäxxþD§øDäj!ā§xäDāäÍ cially available synthetic urine. All samples
Dþx³¸ÿä¸ÿ³¸ÿ§xD§³lø§x³`xä 5x³xÿxî¸ljlxä`ßUxlDîîx Ç߸þlxlUā¸Uäxßþxl³lþløD§äÿxßx
³`§øl³`¸`¸§Dîxj`¸xxD³l`Dßxîîxä D³³øD§3¸`xîā¸
¸ßx³ä`5¸Ā`¸§¸äîä Ǹäîþx
¸ßDî§xDäx¸
îx
¸øßîxäî
`D³x§Çläî³øäßxD§Çxx
߸
D¦xÍ É3'5ÊxxDäî'`î¸Uxß³$³³xDÇ- äøUäîD³`xäçîßxx
߸îxÇD³xl`D-
߸øÇD³lîÿ¸
߸îx¥¸UDÇǧ`D³îä
lacked them. o synthetic urine samples
`¸³îD³xlD³ā¸
îx
¸øßäøUäîD³`xäÍ%xD-
tive results do not prove criminal activity—
but they can indicate attempted deception,
!ā§xäDāäͳäø``DäxäjxDlläjÙîx`§³`
or the business should simply collect another
äÇx`x³
߸îx³lþløD§ÍÚ
$`x§§x0xD`x¸
<ß³D¸¸³-
ÿxD§î7³þxßäîājÿ¸ä3'5ÜäÇßxälx³î
D³lÿD䳸î³þ¸§þxl³îxäîølāj³¸îxäîDî
îxîxäîÿ§§³¸îlxîx`îÇx¸Ç§xÇDä䳸
¸îxßäÜÇxxDäîx߸ÿ³ÍÙ
ä¸x¸³xä`Dßßā-
ing synthetic urine or somebody else’s clean
øß³xjā¸øDþxî¸l¸¸Uäxßþxl`¸§§x`jÚ
äxäDāäÍ0xD`xD§ä¸ÿDß³äîDî
D¦xøß³x Over 75 New Features & Apps in Origin 2019!
makers could easily add substances such as For a FREE 60-day
`Dx³x¸ßîx¸U߸³xî¸îxßÇ߸lø`îäÍ Over 500,000 registered users worldwide in: evaluation, go to
3¸xD§ßxDlāl¸j!ā§xäDāäÍxxÇDäąxä ◾ 6,000+ Companies including 20+ Fortune Global 500 OriginLab.Com/demo
îDîîxäî³øäîîxßx
¸ßx§¸¸¦
¸ß`¸Ç¸ø³lä ◾ 6,500+ Colleges & Universities and enter code: 9246
naturally produced in our bodies (urobilin, in ◾ 3,000+ Government Agencies & Research Labs
îä`DäxÊ͸U³³îDîÿî`¸¸³§ā
consumed substances makes the test even
¸ßxǸÿxß
ø§D³läǸîx³îD§§ā¸ßxÇßD`î-
25+ years serving the scientific & engineering community
`D§îD³ÿDî`³Çx¸Ç§xÇxxÍ Andy Extance
A A S
B I O M I M I C RY
How the Camera Mimics the Shrimp Eye
Crustacean Multidirectional A
A A S
DATA S C I E N C E
database of publications by these hires.
Idea ßäîîxā§¸¸¦xlDî¸ÿþxUlxDä³
computer science spread to new institu-
GREENLAND EGYPT
3`y´ïåïååȹïïymDÀµ®¨yĀmy`àDïyàmmy´Uy¨¹Ā An excavation near Cairo yielded dozens
IN THE NEWS
DĀDïD¨D`yà´´¹àïĀyåïàyy´¨D´mÎ5yĂUy¨yÿy ¹®ù®®ym`DïåÎà`Dy¹¨¹åïåD¨å¹
Quick ï®ïàyÈàyåy´ïD®yïy¹àïy®ÈD`ïjUùï¹ïyàyāÈyàïå
åDĂ®¹àyyÿmy´`yå´yymymï¹Èà¹ÿyïDïïy`àDïyàDå
¹ù´mïĀ¹¨Dày®ù®®ymå`DàDUUyyï¨yå
wrapped in linen and a rare collection of
Hits D´yāïàDïyààyåïàD¨¹à´Î å®D¨¨yàå`DàDU®ù®®yåÎ
By Emiliano
Rodríguez Mega
PALAU
5yï´Ă0D``Dà`Èy¨D¹
Uy`D®yïyàåï`¹ù´ïàĂ
U.S.
ï¹Èà¹Uïïyùåy¹
2å´y`Dàyïïyùåyj¹à
åù´å`àyy´å`¹´ïD´´
ÿDÈ´jD®¹´ïyy´DyàåDå
`¹àD¨ï¹ā`´àymy´ïåj
È๮Èïymïy7Î3ι¹mD´m
´`¨ùm´¹āĂUy´Ć¹´yD´m
àùm®´åïàDï¹´ï¹Uyy
¹`ï´¹āDïyÎ5y®yDåùày
ùÈy¹àïåï¹`¹®UDïĂ¹ùï
¹¨¨¹ĀåD宨Dà¨yå¨Dïÿy
容§´Î5yDy´`ĂD®å
my`å¹´´DĀDïDï
ï¹UD´®y´ï¹¨`Dàyïïyåj
ïD§yåyy`ï´÷Ĉ÷ÀÎ
ày®¹ÿyDÿ¹àym`Dàå๮
ïy®Dà§yïD´màyåïà`ïïy
åD¨y¹ÿDÈyDÿ¹àåÎ
CHILE
'´y¹ïymàyåïȨD`yå¹´yDàïjïyïD`D®D SOUTH AFRICA
yåyàïj娹å´ïå®`à¹UD¨¨yUy`Dùåy¹ 3ïùmy´ïå´DÈy5¹Ā´®DmyUà`§åùå´ùà´y๮
ù´Èày`ymy´ïymàD´åÎàyÕùy´ïàD´D¨¨¹àïy ®y´Ýå﹨yïåj´DU¹`y®`D¨Èà¹`yåå´ÿ¹¨ÿ´UD`ïyàDj
For more details, visit
www.ScientificAmerican.com/
ÈDåïïàyyĂyDàåDå`Dùåymïy®Dååÿyyāï´`ï¹´ `D¨`ù®D´måD´mÎ5yUà`§å¹yàDÈà¹mù`ïÿyD´m
feb2019/advances ¹´DïÿyUD`ïyàD¨åÈy`yåjàyåyDà`åùyåïåÎ ¹m¹à¨yååĀDĂï¹ày`Ă`¨yù®D´ ÈyyÎ
A A S
Join the Polygraph machines also attempt to spot lies.
Community.
Discover
world-changing
science.
M AC H I N E L E A R N I N G
The team trained eri ol on a total of
Lie-Detector ¿j¿öö߸UUxßāßxǸßîäîx³DD§Ç¸§`x
had closed—meaning either the thief had
AI been convicted or the complainant had
confessed to fabricating the crime. t then
Algorithm helps to identify îxäîxl¸ÿD``øßDîx§āîxD§¸ßî`§Dää
fake police reports xlDäDǧx¸
é´ßxǸßîäDäîßøx¸ß
D§äxj
`¸ÇDßxlÿîîÿ¸øD³xĀÇxßîäÍ<xß0¸§
S ain s ationa o ice or s recently ¸øîÇxß
¸ßxlîx`¸ÇäUā¿D³löćÇxß
ÿx§`¸xlD³xÿxUxßiD³Dßî`D§ `x³îjßxäÇx`îþx§āÍ5xßxäø§îäjÇøU§äxl³
³îx§§x³`x§`D§§xl<xß0¸§Íîäîxßäî ø³xöć¿}³Knowledge-Based Systems, have
îxĀîUDäxläāäîx
¸ß
xßßxøîǸ³ā D§ä¸x§ÇxlßxäxDß`xßäø³lxßäîD³l¸ÿ
߸UUxßāßxǸßîäD³lîäDäî¸ø³l³§ā Çx¸Ç§x§xî¸îxǸ§`xÍDUß`DîxlßxǸßîäj
D``øßDîxjßxäxDß`xßääDāÍ
¸ßxĀDǧxjîx³lî¸lxä`ßUxDäÇx``
=x³$øx§DD`¸¸§§Dl¸ä ¸løä¸ÇxßD³lÉîxDîîD`¦xßøäøD§§āÿxDßä
worked as a police inspector in ranada a helmet or attacks from behind). They also
äxþxßD§āxDßäD¸jxUx`Dx
ßøäîßDîxl øäxä¸ßîxßäx³îx³`xäD³l§D`¦³
¸ßD
at how often his team had to deal with DU¸øîîxD`îøD§³`lx³îÍ
߸UUxßā`¸Ç§D³îäîDîîøß³xl¸øîî¸Ux <xß0¸§äD§ßxDlāUx³äø``xää
ø§§ā
D¦xÍÙ$D³ā`¸§§xDøxäÿxßxÿDäî³D§¸î lxǧ¸āxlD`߸ää3ÇD³Í ø³xöć¿èǧ¸î
of time investigating cases that had never îxäî³îx`îxä¸
$øß`DD³l$E§DD
¸``øßßxljÚäDāäDD`¸¸§§Dl¸äj³¸ÿ x§Çxlî¸lxîx`îöD³lð´
D§äx߸UUxßxä
at Spain’s Ministry of nterior in Madrid. ³¥øäxÿxx¦`¸ÇDßxlÿ§ā
ÙîÿDäDÇ߸U§xÍÚ îßxxD³l¿öjßxäÇx`îþx§āj
¸ßîDî
0x¸Ç§x
D¦x߸UUxßxä
¸ßþD߸øäßxD ³îxÇßxþ¸øälx`DlxÍ
sons. Some simply want to avoid telling =§§D=D³jD`¸Çøîxßä`x³îäîDî
D§ā¸ß
ßx³läîxā§¸äîä¸xî³þD§ø îx7³þxßäîā¸
D§
¸ß³Dj3D³îD
DßUDßDj
DU§xUøî¸îxßäl¸îî¸`D䳸³³äøß ÿ¸ÿD䳸î³þ¸§þxl³îxßxäxDß`jä
D³`x`§DäjDD`¸¸§§Dl¸ääDāäÍ7³î§ <xß0¸§Üääø``xää`¸ø§lUxßxǧ`Dîxl³¸îxß
ßx`x³î§ājîx¸³§āäîßDîxā
¸ß`Dî`³ `¸ø³îßxäÇDßî`ø§DߧāÿxßxǸ§`xlxÇDßî
îxÿDäD䦳äxD丳xlǸ§`x¸`xßäî¸ x³îäDßxä¸ßîäîDxlÍDD`¸¸§§Dl¸ä
ßxþxÿäøäÇ`¸øäßxǸßîäjUøîîäDÇÇ߸D` ¸Çxä<xß0¸§ÿ§§D§ä¸Uxøäxlî¸äǸî¸îxß
ALLAN SWART Getty Images
A A S
A N I M A L B E H AV I O R
øD³
D`xÍÙ
äDßxDU§xî¸l¸îxäx
Spitting ßxD§§ā`¸Ç§`DîxlþäøD§îDä¦äÿîDßxD§§ā
äD§§UßD³jîx³DāUxÿx`D³`¸xøÇ
Image ÿîlxßx³îx³³xx߳丧øäÚ
¸ß
D`xßx`¸³î¸³îx`³¸§¸ājäxäDāäÍ
ß`xßä`D³ßx`¸³ąx äDßxäDßîxßîD³Çx¸Ç§xþxîx
`ßxlî
¸ßjäDāä<xßD3`§øxääx§jDą¸¸§¸äî
øD³
D`xäxþx³
߸D³D³§x
Dîîx7³þxßäîā¸
¸³³³xßD³ājÿ¸
ÿD䳸î³þ¸§þxl³îx³xÿäîølāÍÙ0x¸Ç§x
ni ersit of ford ą¸¸§¸äîDî D§ÿDāääDāîDîUx`Døäxä¸xî³ä¸§lxßj
%xÿǸßîäøäÇx`îxlîxDß`xßääx îä¸ßxÇßîþxÍîÜäÔøîxîx¸ÇǸäîxjÚ
ÿDääîølā³`¸ø§lßx`¸³ąxxßÍ5x ß`xßäßxäDÿDîxߥxîDîîäÇßxāÍ 3`§øxääx§äDāäÍß`xßäîDþx
î߸Ç`D§ä¦³¸ÿ³î¸äÇî¥xîä¸
ÿDîxß lxßx³îUßD³D`³xßā
߸øD³äj
Dî³äx`îÇßxāÿ¸ø§lîD¦xDDîxß UāðćjéćD³l´ćlxßxxäD³¸³îßþD§îDä¦Í UøîîxāDßxäDU§xî¸xĀîßDǸ§Dîx¸ÿ
ÿx³äxÿD§¦xl³î¸îx§DU¸ßDî¸ßāÍ 5xxĀÇxßx³îäÿxßx³îx³lxlî¸ ¸U¥x`îä¸¦
߸lxßx³îD³§xä
%xÿǸßîD³lxß`¸§§xDøxää¸ÿxl Ç߸Ux¸ÿäÇxß`xþxîßxxlx³ä¸³D§ D`ßø`D§ä¦§§
¸ßø³î³j³DþDî³D³l
³öć¿éîDîxßä`¸ø§l³lxxlßxx- ¸U¥x`îäjD³l
D`xäDßxÇDßî`ø§Dߧā³îxßxäî- äǸîî³ÇßxlDî¸ßäÍ
UxßøD³þäDxäÍ3xîßD³xlîxî¸ ³xĀDǧxäÍÙ5xāÜßx`¸Ç§`DîxljîxāÜßx 3`§øxääx§ÜäîxDD³l¸îxßäDþx-
äÇxÿÿDîxßDîDxDl¸³þxÿ¸
DäÇx`` Ôøîxl`ø§îî¸ZÇ߸`xää[xþx³
¸ß`¸Çøî- §îxlîxþäøD§`DÇDU§îxä¸
¸îxßäi
`¸Çøîxßßx³lxßxl
D`xjÿ`îxāÇ`¦xl xßäD³lÇx¸Ç§xD³lÿx³ā¸ø߸îDîx ßxāUDU¸¸äDߦä`D³ßx`¸³ąxäDÇxä
¸øîèèî¸}´Çxß`x³î¸
îxîxÍ
øîîx îxjîxā`D³x³DßxD§§ā³îxßxäî³ D³l³DþDîxDąxä
߸x¸ßāçîx
ßxäxDß`xßäll³¸î¦³¸ÿÿDîÿ¸ø§lDÇ- ÿDājÚ%xÿǸßîäDāäÍ U¸³lDäx§ä`D³äxxø§îßDþ¸§xîÇDî-
BIOMECHANIC S
D³l
D§§¸³î¸îxßUxD¦äÍ?xîîDîl¸x䳸î Australian
DÇÇx³Í0Dßä§xÿD³läîxDøäxl`¸- diamond dove
Hop to It Çøîx߸lx§³î¸lä`¸þx߸ÿUßläDþ¸l
îä
DîxÍ5xālä`¸þxßxlîDîUßlä߸îDîx
3îølā³DþD³¥ødzx§Çä
îxßU¸lxää§î§āUD`¦ÿDßlÿ§xD``x§-
ä`x³îäîäUø§lUxîîxß߸U¸îä xßDî³³î¸D¥øÇÍ5xāD§ä¸DþxxĀU§x
§xD³lî¸x¥¸³îäjÿ`Çßxþx³îîx
icture a i eon Çxß`xl¸³Dîx§xǸ³x
߸îD¦³¸UßxāD³lxlDîx§ā
ÿßxÍ2xDlā
¸ßîD¦x¸jîßDäxäîäÿ³äj `ßDä³³î¸îx߸ø³lÍ5xßxäø§îäÿxßx
äÇß³ä³î¸îxDßD³lDÇäDÿDājÇxßDÇä ÇøU§äxl§Däî'`î¸Uxß³Royal Society
ÿîîx³îx³î¸³¸
§xDþ³îä`D§§³`Dßl Open Science.
¸³ā¸øß`DßÜäÿ³läx§lÍ5ääxßxä¸
0Dßä§xÿäx³³xxßä`D³øäxîä
D`äää¸`¸¸³Ç§D`xîDîā¸øÇ߸UD- ³
¸ßDî¸lxä³ß¸U¸îäîDî`D³³¸î
U§āl¸³¸îÇDāîø`Dîîx³î¸³Í
øî7³- ¸³§ā¥øÇÿx§§UøîD§ä¸§Dø³`³î¸î
þxßäîā¸
$D³`xäîxßU¸x`D³`D§x³- ¸ßxx`x³î§āÍ$¸äîøD³x³³xxßxl §³x
¸ßîxßäî¿ćć
xxîjÚxäDāäÍ=§x
³xxß
x³0Dßä§xÿl¸xäÍxäîßā³î¸ ā³D`³xäßxÔøßxxîxߧ¸³ßø³- îx`DßDäî¸ßxþøÇjîx
x§³x`DîDÇø§îä
lxä³ß¸U¸îäîDî`D³¥øǧ¦xUßläÍ ÿDāäÉiDßǧD³xäʸßDîjäîDU§xäøß- îäx§
³î¸Dßø³Í5xäDxÇß³`ǧxø³lxß-
$¸äî`¸³þx³î¸³D§ß¸U¸îä߸§§D߸ø³l
D`xäÉix§`¸Çîxßä¸ßl߸³xäÊ
¸ß §xä¸ÿUßlä³îDîxîÍ
¸³ÿxx§äj`¸³äîßD³³¸U§îāÍ5xßxäD îD¦x¸ÍîxßÿDājîxāîD¦xDÿ§xî¸ Ù
ā¸ø`D³ø³lxßäîD³l¸ÿîDî
³xxl
¸ß¸ßxD§x߸U¸îäîDîÙ`D³¥øÇ ¸þxß`¸xßDþîāD³lD³x§xþDî¸³Í ÿ¸ß¦äjÚDUUDlläjÙā¸ø`D³Uø§lD߸U¸î
¸þx߸UäîD`§xä¸ßlxUßä³`§øîîxßxlx³þ- 7³þxßäîā¸
3¸øîxß³D§
¸ß³DU¸- îDîÜ丸lDîßø³³³D߸ø³lD³l¸¸lDî
߸³x³îäjÚ0Dßä§xÿäDāäÍ5¸lxä³äø`D x`D³äî$`Dx§DUUjÿ¸ÿD䳸î ā³jD³lîÿ§§D§ä¸Ux¸¸lDîîD¦³¸
D`³xjxîøß³xlDîøßxiÙ
ßläDßx ³þ¸§þxl³îxäîølājäDāääÇß³äD³l äøllx³§ā³D§§¦³lä¸
`¸³läD³l§D³l-
ßxD§§ā¸¸l¥øÇxßäjÚx³¸îxäÍ §xþxßäx³DU§x¸ßxßDÇlD``x§xßDîD³ ³¸³DlxÍÚ0Dßä§xÿ䳸ÿlxä³³
5xî߸øU§xäjÿx³UßlääîDßîî¸îD¦x ÿxx§äD³lDĀ§xäl¸Í³lD³āD³D§ä äø`D߸U¸îjDäD³D§îxß³Dîþxî¸ÿxx§xl
¸jîxā§xD³ä¸
Dß
¸ßÿDßlîDîjD``¸ßl³ DßxDäîxßä¸
äÇß³äD³l§xþxßäÍÙ¸øäx ߸þxßä
¸ßxĀǧ¸ß³¸îxßǧD³xîäÍ
ALAMY
The Promise of spices through a metal tube. “What you do with exposure therapy
is systematically go over the trauma,” Difede explains. “We’re
teaching the brain to process and organize the memory so that it
Virtual Reality can be filed away and no longer intrudes constantly in the
patient’s life.” The results, after nine to 12 gradually intensifying
sessions, can be dramatic. One 2010 study with 20 patients found
rom pain relief to mental health, that 16 no longer met the criteria for PTSD after VR treatment.
is poised to reshape patient care Until recently, large-scale studies of VR have been missing in
action. This is changing fast with the advent of cheaper, portable
By Claudia Wallis systems. Difede, Rizzo and three others just completed a random-
ized controlled trial with nearly 200 PTSD patients. Expected to be
f ou sti t ink of virtual reality as the province of dystopian sci- published this year, it may shed light on which patients do best
ence fiction and geeky gamers, you had better think again. Faster with this high-tech therapy and which do not. In a study with her
than you can say “Ready Player One,” VR is starting to transform colleague, burn surgeon Abraham Houng, Difede is aiming to
our world, and medicine may well be the first sector where the quantify the pain-distraction effects of a successor to SnowWorld
impact is profound. Behavioral neuroscientist Walter Greenleaf called Bear Blast, a charming VR game in which patients toss balls
of Stanford University has been watching this field develop since at giggly cartoon bears. They will measure whether burn patients
the days when VR headsets cost $75,000 and were so heavy, he need lower doses of intravenous painkillers while playing.
remembers counterbalancing them with a brick. Today some Greenleaf counts at least 20 clinical arenas, ranging from sur-
weigh about a pound and cost less than $200. Gaming and enter- gical training to stroke rehabilitation to substance abuse where
tainment are driving current sales, but Greenleaf predicts that VR is being applied. It can, for example, help recovering addicts
“the deepest and most significant market will be in clinical care avoid relapses by practicing “refusal skills”—turning down drinks
and in improving health and wellness.” at a virtual bar or heroin at a virtual party. Brain imaging suggests
Even in the early days, when the user entered a laughably low- that such scenes can evoke very real cravings, just as Bravemind
resolution world, VR showed great promise. By the mid-1990s re- can evoke the heart-racing panic of a PTSD episode. Researchers
search had shown it could distract patients from painful medical foresee a day when VR will help make mental health care cheap-
procedures and ease anxiety disorders. One initial success was er and more accessible, including in rural areas.
SnowWorld, which immersed burn patients in a cool, frozen land- In a compelling 2017 paper that reviews 25 years of work, Riz-
scape where they could lob snowballs at cartoon penguins and zo and co-author Sebastian Koenig ask whether clinical VR is
snowmen, temporarily blocking out the real world where nurses finally “ready for primetime.” If today’s larger studies bear out pre-
were scrubbing wounds, stretching scar tissue and gingerly chang- vious findings, the answer seems to be an obvious “yes.”
VENTURES
Wade Roush is host of Soonish, a podcast exploring H S SS A
how technology will shape the future.
Getting Out to build a tech cluster without at least one research university to
generate ideas and qualified employees.
And the ingredient list goes on. A base of older tech firms
of Silicon Valley’s gives future start-up founders a place to train. Federal invest-
ment, which helped to put Silicon Valley’s semiconductor indus-
Shadow try on the map, is a huge boost. Finally, you need local venture
capitalists willing to invest in high-risk enterprises.
Put it all together, and you get what I think of as the proximi-
You don’t need programmers or venture ty effect—a self-sustaining churn of people, inspiration, invest-
ment, intellectual property and profit. It’s no wonder that dozens
capitalists for a thriving local economy of U.S. cities, both large (San Diego, St. Louis) and medium-sized
By Wade Roush (Columbus, Chattanooga), are investing in innovation districts.
But there’s a problem: it can take decades of planning to assem-
Let s sa ou re t e ma or of idd e a e, a (fictional) medi- ble all the components of a cluster, and you can’t invest in just
um-sized city in Texas. The coal-fired electric power plant out- one element while ignoring the others.
side town just closed, and the steel mill in the next county over Floridians paid a lot to learn that lesson. Between 2003 and
has gone bankrupt. Now voters expect you to do something 2008 then governors Jeb Bush and Charlie Crist arranged hun-
about rising unemployment and the shrinking tax base. You dreds of millions of dollars in subsidies to bring biotech labora-
might look at America’s booming metropolitan areas, such as tories such as the Max Planck Florida Institute for Neuroscience
Boston, Seattle or Silicon Valley, and say what we need here is to the Palm Beach County area. The private-sector spin-offs
an “innovation district” or a “technology cluster.” Bush and Crist had promised never emerged, and between 2007
Sounds great! But it’s rarely the full answer. and 2012 the state’s spending spree had brought fewer than
1,000 new jobs to Florida. “We didn’t have the infrastruc-
ture that was needed to develop the industry at a rapid
pace,” the president of the Business Development Board
of Palm Beach County told reporters.
Fortunately, cities don’t need to follow the classic clus-
ter model. There’s new evidence that regions can develop
fast-growing business scenes even if some of the tradition-
al cluster ingredients are sparse or missing. The Detroit
area, for example, is home to only a handful of venture
firms. But it’s developing a distinctive mix of start-ups
focused on what Detroit does best: manufacturing, robot-
ics and next-generation transportation technologies, with
a dose of software. Ted Serbinski, managing director of
Detroit’s Techstars Mobility incubator, has called it “the
intersection of steel and bits.”
In fact, quite a few of the metro areas that show the
strongest start-up growth lately fall outside the tradition-
al cluster definition. In the Ewing Marion Kauffman
You certainly wouldn’t be the first public official to fall under Foundation’s 2017 rankings of start-up growth, the Columbus,
technology’s spell. After all, when high-growth companies flock Nashville and Atlanta metropolitan areas placed third, fourth
to a specific location, jobs and higher incomes do tend to follow. and fifth, respectively. All have strong universities. But none
Take the Kendall Square cluster, loosely defined as the area with- has a major tech-industry legacy or a substantial venture-
in a 10-minute walk of the subway station at the Massachusetts capital community.
Institute of Technology. It’s home to more than a dozen top bio- As mayor of Middlevale, you’re not going to build a research
tech firms. Google, Microsoft, Amazon and Facebook all have university from scratch or lure a flock of venture firms to town.
research outposts here. And some 750 start-ups incubate at the But you can focus on the skills your citizens already have and
Cambridge Innovation Center. It’s all helped to give Cambridge look for ways to match those with the more digital, distributed,
the lowest unemployment rate in Massachusetts and a family globalized economy of the 21st century. Admire the clusters—
income 59 percent above the national median. and then go your own way.
Of course, the city is also home to high-paying institutions
H SA L
like Harvard University and M.I.T. But that, too, is part of the isit 2_w²í_Ĉ¬wÞ_C² on acebook and Twitter
canonical definition of a cluster. Business scholars say it’s hard or send a letter to the editor: editors sciam com
NEUROSCIENCE
FACE
VALUES
Brain regions that process faces reveal deep insights
into the neural mechanisms of vision
By Doris Y. Tsao
WHEN I WAS IN HIGH SCHOOL, I LEARNED ONE DAY ABOUT THE DENSITY OF CURVES
in an introductory course on calculus. A simple pair of differential equa-
tions, which model the interactions of predators and prey, can give rise
to an infinite number of closed curves—picture concentric circles, one
nested within another, like a bull’s-eye. What is more, the density of
these curves varies depending on their location.
This last fact seemed so strange to me. I could easily imagine a finite
set of curves coming close together or pulling apart. But how could an
infinity of curves be denser in one region and less dense in another?
I soon learned that there are different types of infinity, which have para-
doxical qualities, like Hilbert’s Hotel (where the rooms are always fully
booked but new guests can always be accommodated) and the
Banach-Tarski apple (which can be split into five pieces and rearranged
to make two apples of equal volume as the original). I spent hours poring
over these mathematical proofs. Ultimately they struck me as symbolic
magic of no real consequence, but the seed of interest had taken root.
Later, as an undergraduate at the faces than to images of any other ob- a slightly larger number of neurons
California Institute of Technology, I ject when a person was inside a responsive to faces, like icebergs
learned about the experiments of functional magnetic resonance im- randomly clustered at sea.
David Hubel and Torsten Wiesel and aging (fMRI) brain scanner. The pa- Because I had done the imaging
their landmark discovery of how a per seemed bizarre. I was used to experiment in a monkey, I could di-
region in the brain called the prima- the brain being made of parts with rectly address this concern by in-
ry visual cortex extracts edges from names like basal ganglia and orbito- serting an electrode into an fMRI-
Doris Y. Tsao is a the images relayed from the eyes. I frontal cortex that had some vague identified face area and asking,
professor of biology
realized that what had actually mys- purpose one could only begin to What images drive single neurons in
at the California In-
stitute of Technology tified me back in high school was fathom. The concept of an area spe- this region most strongly? I per-
and an investigator the act of trying to imagine different cifically devoted to processing faces formed this experiment together
of the Howard Hughes densities of infinity. Unlike the seemed all too comprehensible and with Winrich Freiwald, then a post-
Medical Institute. She mathematical tricks I had studied in therefore impossible. Anyone could doctoral fellow in Margaret Living-
is also direc tor of the high school, the edges that Hubel make a reasonable conjecture about stone’s laboratory at Harvard, where
Tianqiao and Chrissy
and Wiesel described are processed the function of a face area—it should I was a graduate student. We pre-
Chen Center for
Systems Neuroscience by neurons, so they actually exist in probably represent all the different sented faces and other objects to a
at Caltech. In October the brain. I came to recognize that faces that we know and something monkey while amplifying the elec-
she was named a visual neuroscience was a way to un- about their expression and gender. trical activity of individual neurons
MacArthur Fellow. derstand how this neural activity As a graduate student, I had used recorded by the electrode. To moni-
gives rise to the conscious percep- fMRI on monkeys to identify areas tor responses in real time, the neu-
tion of a curve. activated by the perception of three- rons’ electrical signals were convert-
The sense of excitement this re- dimensionality in images. I decided ed to an audio signal that we could
alization triggered is hard to de- to show pictures of faces and other hear with a loudspeaker in the lab.
scribe. I believe at each stage in life objects to a monkey. When I com- This experiment revealed an as-
one has a duty. And the duty of a pared activation in the monkey’s tonishing result: almost every single
college student is to dream, to find brain to faces with activation to oth- cell in the area identified through
the thing that captures one’s heart er objects, I found several areas that fMRI was dedicated to processing
and seems worth devoting a whole lit up selectively to faces in the tem- faces. I can recall the excitement of
life to. Indeed, this is the single poral lobe (the area underneath the our first recording, hearing the “pop”
most important step in science—to temple)—specifically in a region of cell after cell responding strongly
IN BRIEF find the right problem. I was capti- called the inferotemporal (IT) cor- to faces and very little to other ob-
Understanding vated by the challenge of under- tex. Charles Gross, a pioneer in the jects. We sensed we were on to
vision remains one standing vision and embarked on a field of object vision, had discovered something important, a piece of cor-
of the grand chal- quest to learn how patterns of elec- face-selective neurons in the IT cor- tex that could reveal the brain’s
lenges that neurosci- trical activity in the brain are able tex of macaques in the early 1970s. high-level code for visual objects.
entists confront. to encode perceptions of visual ob- But he had reported that these cells Marge remarked on the face patch-
One key aspect of jects—not just lines and curves but were randomly scattered through- es: “You’ve found a golden egg.”
this problem relates even objects as hard to define as out the IT cortex. Our fMRI results I also remember feeling sur-
to the way the brain
faces. Accomplishing this objective provided the first indication that prised during that first experiment.
my´ïyåD`yåjïy
most important required pinpointing the specific face cells might be concentrated I had expected the face area would
social emblem. brain regions dedicated to facial into defined regions. contain cells that responded selec-
Neurons ´my´ym recognition and deciphering their tively to specific individuals, analo-
sections of the cere- underlying neural code—the means FACE PATCHES gous to orientation-selective cells in
UàD¨`¹àïyāj`D¨¨ym by which a pattern of electrical im- AFTER PUBLISHING MY WORK, I was in- the primary visual cortex that each
D`yÈDï`yåjDày pulses allows us to identify people vited to give a talk describing the respond to a specific edge orienta-
dedicated to recog- around us. fMRI study for a faculty position at tion. In fact, a number of well-publi-
nizing faces.
The journey of discovery began Caltech, but I was not offered the cized studies had suggested that
Uncovering the
organization of the in graduate school at Harvard Uni- job. Many people were skeptical of single neurons can be remarkably
face-patch system versity, where I studied stereopsis, the value of fMRI, which measures selective for the faces of familiar
served as a prelude the mechanism by which depth per- local blood flow, the brain’s plumb- people—responding, say, only to
to deducing the ception arises from differences be- ing. They argued that showing in- Jennifer Aniston. Contrary to my ex-
underlying compu- tween the images in the two eyes. creased blood flow to a brain area pectation, each cell seemed to fire
tations that the One day I came across a paper by when a subject is looking at faces vigorously to almost any face.
brain makes to neuroscientist Nancy Kanwisher, falls far short of clarifying what I plugged madly away at Photo-
identify faces.
now at the Massachusetts Institute neurons in the area are actually en- shop during these early experi-
This neural code
may serve as a of Technology, and her colleagues, coding because the relation be- ments and found that the cells re-
Rosetta stone for reporting the discovery of an area in tween blood flow and electrical ac- sponded not just to faces of humans
representing other the human brain that responded tivity is unclear. Perhaps by chance and monkeys but even to highly
objects besides faces. much more strongly to pictures of these face patches simply contained simplified cartoon faces.
can you be sure it’s a face cell and patches, moreover, are not random- tiny amounts of current—a tech-
not a pomegranate cell or a lawn ly scattered throughout the IT cor- nique called microstimulation—
mower cell? This result nailed it for tex. They are located in similar loca- while the monkey was inside an
me. The precise match between the tions across hemispheres in each fMRI scanner. The goal was to find
way cells reacted to changes in con- animal. Moreover, work by our out what other parts of the brain
trast between different parts of the group and others has found that a light up when a particular face
face and Sinha’s computational pre- similar pattern of multiple face patch is stimulated. We discovered
diction was uncanny. patches spanning the IT cortex ex- that whenever we stimulated one
Our initial experiments had re- ists in humans and other primates face patch, the other patches would
vealed two nearby cortical patches such as marmosets. light up but not the surrounding
that lit up to faces. But after further This observation of a stereotyped cortex, indicating that, indeed, the
scanning (with the help of a con- pattern suggested that the patches face patches are strongly intercon-
trast agent that increased several- might constitute a kind of assembly nected. Furthermore, we found that
fold the robustness of the signal), it line for processing faces. If so, one each patch performs a different
became clear that there are actually would expect the six patches to be function. We presented pictures of
six face patches in each of the connected to one another and each 25 people, each at eight different
brain’s two hemispheres (making a patch to serve a distinct function. head orientations, to monkeys and
dozen golden eggs total). They are To explore the neural connec- recorded responses from cells in
distributed along the entire length tions among patches, we electrically three regions: the middle lateral
of the temporal lobe. These six stimulated different patches with and middle fundus patches (ML/
MF), the anterior lateral patch (AL)
and the anterior medial patch (AM).
We found striking differences
Shape + Appearance = Face among these three regions. In ML/
MF, cells responded selectively to
Identifying the face patches ÿD丳§āDßäîäîxÇÍîîx³Ux`Dx³x`xääDßāî¸xĀǧ¸ßxÿDîDÇ- specific views. For example, one cell
Çx³ä³îx³xø߸³äÿî³xD`ÇDî`jäxîDäxDß`
¸ßîxUßD³Üä`¸l³ä`xx
¸ß
D`- might prefer faces looking straight
es. To derive quantitative measures for faces, the Tsao laboratory came up with 25 features for ahead, whereas another might opt
shape and 25 for appearance that could be used by each neuron in a face patch—a 50-dimen- for faces looking to the left. In AL,
丳D§
D`xäÇD`xÍ5xäDÇx
xDîøßxä`D³Uxî¸øî¸
Däî¸äxlx³³îxä¦x§x¸ÿ cells were less view-specific. One
ÿlxîxxDlä¸ßîxläîD³`xUxîÿxx³îxxāxäÍ5xDÇÇxDßD³`x
xDîøßxääÇx`
āîx
D`xÜä class of cells responded to faces
surface texture (complexion, eye or hair color, and so on). looking up, down and straight
ahead; another responded to faces
A WIN-WIN BET
AT A MEETING in Ascona, Switzer-
land, I presented our findings on
how we could reconstruct faces us-
ing neural activity. After my talk,
Rodrigo Quian Quiroga, who dis-
covered the famous Jennifer
Aniston cell in the human medial
temporal lobe in 2005 and is now
at the University of Leicester in
England, asked me how my cells
related to his concept that single
neurons react to the faces of specif-
ic people. The Jennifer Aniston
cell, also known as a grandmother
Corresponding Reconstructed Faces Based on Neuron Activity cell, is a putative type of neuron
that switches on in response to the
face of a recognizable person—a
celebrity or a close relative.
The resulting images constituted In our experiment, we randomly I told Rodrigo I thought our
the appearance of the faces inde- drew 2,000 faces and presented cells could be the building blocks
pendent of shape. them to a monkey while recording for his cells, without thinking very
We then performed principal cells from two face patches. We deeply about how this would work.
components analysis independent- found that almost every cell showed That night, sleepless from jet lag, I
ly on the shape and appearance de- graded responses—resembling a recognized a major difference be-
scriptors across the entire set of ramp slanting up or down—to a tween our face cells and his. I had
faces. This is a mathematical tech- subset of the 50 features, consistent described in my talk how our face
nique that finds the dimensions with my earlier experiments with cells computed their response to
that vary the most in a complex cartoon faces. But we had a new in- weighted sums of different face fea-
data set. sight about why this is important. If tures. In the middle of the night, I
By taking the top 25 principal a face cell has ramp-shaped tuning realized this computation is the
components for shape and the top to different features, its response same as a mathematical operation
25 for appearance, we created a can be roughly approximated by a known as the dot product, whose
50-dimensional face space. This simple weighted sum of the facial geometric representation is the
space is similar to our familiar 3-D features, with weights determined projection of a vector onto an axis
space, but each point represents by the slopes of the ramp-shaped (like the sun projecting the shadow
a face rather than a spatial location, tuning functions. In other words: of a flagpole onto the ground).
and it comprises much more than Remembering my high school
DORIS Y. TSAO Êf ace images)
just three dimensions. For 3-D response of face cells = weight linear algebra, I realized this im-
space, any point can be described matrix × 50 face features plied that we should be able to con-
by three coordinates (x,y,z). For a struct a large “null space” of faces
50-D face space, any point can be We can then simply invert this for each cell—a series of faces of
described by 50 coordinates. equation to convert it to a form that varying identity that lie on an axis
perpendicular to the axis of projec- to the amount of red in any color. cause philologists knew Ancient
tion. Moreover, all these faces Such a cell would fire at the same Greek, they could use the Rosetta
would cause the cell to fire in exact- intensity for a brown or yellow col- stone to help decipher Egyptian hi-
ly the same way. or containing the same amount of eroglyphics and Demotic. Similarly,
And this, in turn, would suggest red mixed in with other colors. Face faces, face patches and the IT cor-
cells in face patches are fundamen- cells use the same scheme, but in- tex form a neural Rosetta stone—
tally different from grandmother stead of just three axes, there are one that is still being deciphered.
cells. It would demolish the vague 50. And instead of each axis coding By showing pictures of faces to
intuition everyone shared about the amount of red, green or blue, monkeys, we discovered face patch-
face cells—that they should be each axis codes the amount of devi- es and learned how cells within
tuned to specific faces. ation of the shape or appearance of these patches detect and identify
I was the first person in the any given face from an average face. faces. In turn, understanding cod-
meeting’s breakfast hall at 5 A.M. It would seem then that the ing principles in the face-patch net-
the next morning and hoped to Jennifer Aniston cells do not exist, work may one day lead to insight
find Rodrigo so I could tell him at least not in the IT cortex. But into the organization of the entire
about this counterintuitive predic- single neurons responding selec- IT cortex, revealing the secret to
tion. Amazingly, when he finally tively to specific familiar individu- how object identity more generally
showed up, he told me he had the als may still be at work in a part of is encoded. Perhaps the IT cortex
exact same idea. So we made a bet, the brain that processes the output contains additional networks spe-
and Rodrigo allowed the terms to of face cells. Memory storage re- cialized for processing other types
be framed in a way that would be gions—the hippocampus and sur- of objects—a whirring factory with
win-win for me. If each cell really rounding areas—may contain cells multiple assembly lines.
turned out to have the same re- that help a person recognize some- I also hope that knowing the
sponse to different faces, then I one from past experience, akin to code for facial identity can help ful-
would send Rodrigo an expensive the famed grandmother cells. fill my college dream of discovering
bottle of wine. If on the other hand, Facial recognition in the IT cor- how we imagine curves. Now that
the prediction did not pan out, he tex thus rests on a set of about 50 we understand face patches, we can
would send me solace wine. numbers in total that represent the begin to train animals to imagine
In search of an answer back in measurement of a face along a set faces and explore how neural activ-
our lab at Caltech, Le Chang first of axes. And the discovery of this ity is shaped by the purely internal
mapped the preferred axis for a giv- extremely simple code for face act of imagination. Lots of new
en cell using responses to the 2,000 identity has major implications for questions arise. Does imagination
faces. Then he generated, while still our understanding of visual object reactivate the code for the imag-
recording from the same cell, a representation. It is possible that ined face in the face patches? Does
range of faces that could all be all of the IT cortex might be orga- it bring back even earlier represen-
placed on an axis perpendicular to nized along the same principles tations of contours and shading
the cell’s preferred axis. Remark- governing the face-patch system, that provide inputs to the face-
ably, all these faces elicited exactly with clusters of neurons encoding patch system? We now have the
the same response in the cell. The different sets of axes to represent tools to probe these questions and
next week Rodrigo received an ex- an object. We are now conducting better understand how the brain
quisite bottle of Cabernet. experiments to test this idea. sees objects, imagined or real.
The finding proved that face Because almost all the brain’s
cells are not encoding the identities NEURAL ROSETTA STONE core behaviors—consciousness, vi-
of specific individuals in the IT cor- IF YOU EVER GO to the British Muse- sual memory, decision-making, lan-
tex. Instead they are performing an um, you will see an amazing arti- guage—require object interactions,
axis projection, a much more ab- fact, the Rosetta stone, on which a deep understanding of object
stract computation. the same decree of Memphis is perception will help us gain insight
An analogy can be made to col- engraved in three different lan- into the entire brain, not just the
or. Colors can be coded by specific guages: Egyptian hieroglyphics, visual cortex. We are only starting
names, such as periwinkle, celan- Demotic and Ancient Greek. Be- to solve the enigma of the face.
dine and azure. Alternatively, one
can code colors by particular com-
binations of three simple numbers MORE TO EXPLORE
that represent the amount of red, The Code for Facial Identity in the Primate Brain. Le Chang and Doris Y. Tsao in Cell, <¹¨ÎÀêµj%¹ÎêjÈDyåÀĈÀñÀĈ÷~è ù´yÀj÷ĈÀéÎ
green and blue that make up that How Do We Recognize a Face? Rodrigo Quian Quiroga in Cell, <¹¨ÎÀêµj%¹ÎêjÈDyåµéµééè ù´yÀj÷ĈÀéÎ
color. In the latter scheme, a color FROM OUR ARCHIVES
cell performing a projection onto The Face as Entryway to the Self. àåï¹!¹`è¹´å`¹ùå´yåå2ymùājIY_[dj_ÒY7c[h_YWdC_dZ" D´ùDàĂëyUàùDàĂ÷ĈÀÎ
the red axis would fire electrical
cientificamerican c m ma a ine a
impulses, or spikes, proportional
| GHO ST | FLOWER S |
N 1912, ON THE ANCIENT LAVA FIELDS OF HALEAKAL A– ON THE HAWAIIAN ISLAND OF MAUI, A SINGLE
I tree stood near death. Fifteen feet tall, its bark encrusted with lichens, it was down
to its last flower.
The Hawaiians called this tree hau kuahiwi, the mountain hibiscus. Unlike the more
familiar Hawaiian hibiscus, which grows in moist valleys and opens wide in a welcom-
ing aloha, the mountain hibiscus grew only on the dry, well-drained lava fields of
Hawaii’s volcanoes. The plant unfolded only two of its five hibiscuslike petals, keeping
the rest closed in a demure, curved tube designed for Maui’s honeycreepers—nectar-eating
songbirds with curved bills that were its favored pollinators.
1 2
SPECIMENS PHOTOGRAPHED AT HERBARIUM OF ARNOLD ARBORETUM AND GRAY HERBARIUM OF HARVARD UNIVERSITY
nology with some of the first Ph.D.s in synthetic biology awarded bacteria to produce hydrogen fuel and created art based on the
for that specialization. His firm is also highly specialized: if an- shapes of antibodies. Warm and witty, she was drawn to research
other company needs a new microbe to produce some valuable that probed the borderlands between natural and unnatural and
molecule—for fuel, fiber, fragrance, pharmaceutical, whatever— opened up interesting conversations about genetically modified
Ginkgo will design and test hundreds of prototypes in its bio- organisms. A perfume of extinct florals that people could smell
foundries and hand over the top performers. while meditating on these lost species was right up her alley. She
Many of Ginkgo’s best clients are in the flavors and fragranc- dubbed the venture “Project Cretaceous,” after the period when
es industry, where raw ingredients can be astronomically ex- flowers first came into existence. She began by contacting ex-
pensive. All those fragrance molecules are produced by enzymes perts in Ice Age excavations, who told her it was impossible to se-
in the plant cells, and the blueprint for those enzymes is coded quence a full genome out of the gunky specks of plant that
in DNA by a gene. Like software, this code can run on any com- emerge from the permafrost. The Ice Age was a dead end.
patible platform, and life is surprisingly platform-agnostic. All Before giving up, Agapakis did what any good Millennial
living things use the same four-letter language of DNA—compo- would do: she googled “extinct plant DNA sequencing.” Far down
nents labeled A, T, C and G—and yeast and plants run many of the list of results, she found an obscure paper from the Biological
the same genes. By inserting fragrance genes into specially engi- Journal of the Linnean Society on museomics, a new technique
neered strains of brewer’s yeast, Gink- for extracting DNA from museum-pre-
go brews scent molecules in a flask, served plants and animals. So she did
just like making beer. “The planet has not need permafrost after all. She just
At the trade show, Kelly met a con- needed an herbarium.
sultant for Givaudan, the Swiss per- spent hundreds of The realization made the Harvard
fume giant, who told Kelly about Gi-
vaudan’s Scent Trek program, which
millions of years grad smile. She knew just where to
find one of those.
dispatched explorers into the world’s evolving DNA. And
rain forests to capture the air around THE DNA SEARCH
rare flowers so the scents could be we just have to let it THE HARVARD HERBARIA, which date
identified. Kelly was intrigued. If Gink- go away? For a back to 1842, anchor one brick-lined
go could get samples of these plants, end of a street named Divinity Avenue,
the company could sequence the biological designer, and their numerous floors are filled
genes and synthesize the enzymes
that made the smells. But as the two
it’s frustrating.” with formaldehyde-scented cabinets
holding more than five million sam-
brainstormed, Kelly had a much cra- —Jason Kelly, ples. They do not embrace change en-
zier idea. What if he was able to go be- Ginkgo Bioworks thusiastically, so when Agapakis
yond obscure plants and bring back pitched her plan in 2016, the curator
the scent of flowers that no longer was skeptical. Do what with their
even existed? plants? The herbaria were not in the business of giving away
This would be the first step, he thought, in reversing a tre- their collection to for-profit entities. Besides, they had no search-
mendous biological waste. “The planet has spent three billion able database for their holdings, so they had no idea if they had
years trying out different DNA sequences through this process any extinct plants or not.
we call evolution,” Kelly says, “and that’s what we have today. But It took Agapakis months of negotiations to reach an agree-
along the way, a lot got lost for some random reason—a meteor or ment. The deal was sealed when she offered to provide genomes
whatever—and some of that stuff was incredible. The planet of any extinct plants she found to the research community. Even
spent hundreds of millions of years evolving DNA. And we just so, she had to find the plants on her own, with no help from
have to let it go away? For a biological designer, it’s frustrating to herbaria staff, and if she did find what she was looking for
imagine losing all that great code.” she could not take more than a pinky-nail-sized fragment of ex-
Kelly’s original plan riffed on Jurassic Park: Recover an Ice traneous material.
Age flower from the Arctic permafrost, sequence its genes and Agapakis and Dawn Thompson, Ginkgo’s head of Next Gener-
synthesize the ones responsible for fragrance, then put them in ation Sequencing, printed out the IUCN Red List of 116 modern
yeast cells. When the genes instructed the cells to make the fra- plant extinctions and began their quest. The collection was ar-
grant molecules, Kelly could brew up a little Extinction N° 5. ranged by plant family first and geography second, so the only
It was a long shot. Although a handful of ancient genes had way to find a sample was to go to the corresponding floor of the
been reconstructed in labs, most simply sat there, never being herbaria, find the aisle for the right family and then search in all
asked to produce a protein and thus rejoin our world. Even if the folders for the particular country or area. The aisles were end-
Ginkgo was able to rebuild old genes, those genes might not less, the cabinets seemingly filled with everything but the plants
function in new yeast. Kelly also worried about tying up precious they were looking for. Then, in the Hawaii room, Agapakis
resources. Everyone at his company was already overworked. cranked a big wheel to roll the creaking cabinets apart, opened
The last thing they needed was to get sucked into a Jurassic lark. the doors, paged through the folders, opened one, and gazed down
But the project found a champion in Christina Agapakis, at three long twigs holding an array of broad, beautiful leaves and
Ginkgo’s creative director. Agapakis earned her Ph.D. in synthet- a single pressed flower bud. “Flora of the Hawaiian Islands” read
ic biology at Harvard University, and she worked on optimizing the attached card. “Hibiscadelphus wilderianus.” Agapakis felt an
Road to Resurrection
ß³³x³xäUD`¦
߸îxlxDl䳸îäǧāDDîîx߸
³l³
D³`x³î%Í5xx³xî`DîxßD§Däî¸Uxßx
D丳xl³î¸
Dÿ¸ß¦³x³xîDî`D³³äîßø`îD`x§§î¸D¦x¸§x`ø§xäÍ
Dried 5xx³x³îä`Däx
߸D³xĀî³`îDÿDD³Ç§D³î`D§§xl
Hibiscadelphus
D¸ø³îD³Uä`øäîx³Däî¸UxǧD`xl³î¸D³xÿj§þ³
wilderianus specimen
¸äîÍ3ā³îxî`U¸§¸äîäD¸
¸ÿ¸ß¦ä³äxßîxlîxx³x
³î¸āxDäîjÿxßxîD`îøD§§āDlx
ßDßD³î`¸Ç¸ø³läÍ
1 From dried plant samples,
researchers extract tiny
DNA fragments.
A A A T C G G G G C T A G
G A T
2 The fragments are analyzed C A C G A T T
in a sequencer machine, A G G C C A
which reads the order of their T A G T
DNA fragments Sequencer
component nucleotides
(dubbed A, T, C and G).
A C G T A A G G T G T T T A A A G T T A G A G G C C A A G T A G G G G C T A G T C A C G A T T C C T G A T G
electric thrill. It was Wilder’s extinct tree, right in front of her. ing at Ginkgo, was tasked with this book-reassembly problem.
In the end, the scientists found 20 of the plants on their list He realized those modern SQSs could serve as the template. It
in the herbaria, 14 of which had enough material to spare. Under was like trying to reconstruct a lost version of the Bible using the
the baleful eye of the curator, they snapped off the least impor- King James and New International versions as guides. The
tant bits and placed them in plastic baggies. wording would not exactly match, but they would be a decent
Then it was time for the hard part. DNA degrades after an or- guide to what went where.
ganism dies. Ginkgo was going to have to find needles of DNA in Bit by bit, Wang built his genes on the scaffolding modern
haystacks of cellulose. And the team had only enough material relatives provided, relying on sequence overlaps for placement.
for a few attempts. The researchers decided to practice on an He filled in any missing letters of DNA from the modern tem-
oak leaf scavenged from the streets of Boston. Even that did not plates. If his fragmented Bible read “In th_ beg_ _ning was the
go well. Despite their state-of-the-art sequencing equipment, W_ _ d,” he could look to the King James and be pretty confident
they struggled to extract DNA from the samples. The ancient which letters were missing.
samples did not produce anything. Ultimately Wang was able to reconstruct 2,738 versions of genes
With pressure mounting to yield the sequencing machine to from the extinct flowers. Undoubtedly these strings of biological
paying projects, Agapakis and Thompson had a sobering con- letters had a few typos. Would that ruin their functions? Occasion-
versation. If they kept trying, they were going to run out of plant ally a single wrong letter of DNA will break a gene catastrophically,
material, and there was no way they were getting more. They de- as in sickle cell anemia. But often minor changes do not affect the
cided to put Project Cretaceous on hold until they found a more end product. In fact, sometimes genes with significantly different
effective way of doing it. forms will function similarly. In Biblical terms, “In the begin-
Months later, at a conference, Kelly met Beth Shapiro, co-di- ning was the Word” (King James) and “The Word was first” (The
rector of the Paleogenomics Lab at the University of California, Message) do not match letter by letter, but both get the job done.
Santa Cruz. This is the place you go if you want to de-extinct a Wang thought most of his letter strings would be too glitchy. He
mammoth or a passenger pigeon. Every year it gets better and just hoped a few would work as instructions for a real cell.
better at extracting tiny amounts of DNA from iffy old material. For that to happen, these genes, which existed solely in
In 2016 the lab was able to identify 0.01 to 0.05 percent mam- Wang’s computer, had to be converted into physical DNA. That
moth DNA—a mere whiff of pachyderm—in 5,650-year-old lake is a fairly straightforward job, done with a DNA printer that re-
sediments from an island in the Bering Strait. Send us your sembles a 3-D printer but shoots out As, Cs, Gs and Ts, which
flowers, Shapiro said. bind together chemically into a classic double helix. Although
Thompson overnighted her plastic baggies of leaf matter to this is often called synthetic DNA, it is just as real as any other
Josh Kapp, a grad student in the Paleogenomics Lab. Kapp did DNA. Molecules are molecules.
not like what he saw. He pulverized each sample into powder to Then it was up to the yeast, each of the 2,000-odd genes go-
maximize the surface area, but the plants did not powder as ing into a colony bred to accept new DNA and make molecules
nicely as the bone he was used to. But after many filtration steps according to its instructions. For several days the colonies
and some creative applications of chemicals that bind to DNA frothed like beer brewing in their tiny containers. Scott Marr, a
fragments, Kapp ended up with 14 microtubes holding the se- molecular microbiologist at Ginkgo, watched, wondering what
crets of lost plants, which he packed in dry ice and sent back to they had made. When the fermentation subsided, Marr ran a
Ginkgo. When Thompson ran the samples through her sequenc- sample of each colony through a mass spectrometer, a kind of
ing machine in Boston, she was thrilled to see numerous short artificial nose that was capable of detecting and identifying the
reads come through: millions of fragments of genetic code, each minuscule amount of molecules being produced in each strain.
just 40 or 50 letters long. Each mass shows up as a differently sized peak on a graph. It
was Marr’s job to read the pattern of peaks like a fingerprint.
RECONSTRUCTION IN ACTION He wrote programs to eliminate all the regular products of
BUT DID ANY OF THOSE fragments belong to a scent gene, and could yeast metabolism in the machine’s readout, so only nonyeast
they be put back together? Ginkgo was looking for genes, typi- SQS products—scent-making sesquiterpenes—would show up.
cally about 1,700 letters long, that made enzymes called sesqui- Mindful of the long odds and the likelihood of typos in the Gink-
terpene synthases (SQSs); these are the enzymes that stitch to- go translations, Marr crossed his fingers and ran the samples.
gether most good floral scent molecules. A typical flower might The readouts showed nothing. Then more nothing. It looked like
have several of these genes. With all the tiny fragments they had the scientists had pieced together book passages with too many
recovered, it was as if the Ginkgo researchers had a book for letter mistakes, paragraphs that no cell could read.
each plant—the extinct plant genome—all chopped up into ran- And then there it was: a peak. After a while, there was anoth-
dom 50-letter chunks and mixed together, and they needed to er and another. Marr let out a pent-up breath and began to
reassemble a few 1,700-letter passages in just the right way. match the molecular fingerprints to his database of terpenes.
If the scientists had copies of the original books to use as a Then he broke the good news to the Project Cretaceous team:
template or even a few chapters, they could figure out where the dozens of the flower-yeast chimeras were alive.
fragments went. Here evolution came to the rescue. It never in- Agapakis sat at a table, listening to Marr’s report and taking
vents anything from scratch. New species evolve from older spe- it all in. It had been three years since the initial crazy idea. Many
cies, tweaking or repurposing the original genes. So most SQS times she and her colleagues had nearly abandoned it. And now
genes in modern plants share a lot of DNA code with closely re- they had molecules. Real molecules! Made by genes that had not
lated ancestors. Jue Wang, a computational biologist then work- existed in a century!
1 2
BACK IN THE REAL WORLD Lurking in the background of several samples was a smoky
GINKGO’S YEAST was able to get genes from three different extinct hint of sulfurous dirt. Kelly’s eyes twinkled as he held one under
plants to produce sesquiterpenes. Although the microscopic his nose. “This is pretty magical, to be honest,” he said. “I hope it
amounts were far too small to smell directly, the scientists had captures people’s imagination and gets them to think about
some inklings of what the eventual floral nature might be, based what we’ve lost.”
on the smells of modern counterparts. One of the plants, the The scent—and the thoughts it inspires—is an important
Falls-of-the-Ohio scurfpea—a legume that made the fatal mis- milestone, says Stanford University bioengineer Megan Palmer,
take of growing only on a few rocky islets in the Ohio River that a board member of Revive & Restore, a nonprofit that is sup-
were drowned by dams in the 1920s—produced a handful of ses- porting the passenger pigeon and woolly mammoth resurrec-
quiterpenes that, if some 21st-century relatives were any guide, tion projects. “We can’t know exactly what these flowers smelled
would have woody, peppery, balsamic scents. like,” she says, “but we can get molecular hints that we interpret
The Wynberg conebush—a five-foot-tall flower with white pet- through what we know about the species we see in the world to-
als and a yellow head that grew in the granite hills above Cape day.” As scientific advances, she adds, “these techniques can
Town until 1806, when it disappeared forever underneath South help us make smarter guesses at how extinct species functioned.
Africa’s expanding vineyards—produced an astonishing 21 ses- They may even allow more ambitious projects to restore those
quiterpenes, many of which are associated with tantalizing functions and the species that gave rise to them.”
scents: jasmine, lemongrass, cannabis, chamomile, turmeric, Because of this work, we are a tiny bit closer to coaxing sa-
ginger, hops. That awkward mix ber-toothed tiger musk or Neandertal
sounded like a good match for a flower hemoglobin out of cells. And as more
that had been noted for its “strong and Because of this work of these freelance genes return to
disagreeable smell.” function in new forms, they make us
Eleven sesquiterpenes came from with ancient flowers, begin to question our old emphasis
H. wilderianus, the mountain hibis-
cus, which had last released its es-
we are a tiny bit on species. The traditional genetic
container may not limit the life of its
sence to the world in 1912, as Gerrit closer to coaxing contents. Sitting in that Boston con-
Wilder picked that final flower and
descended Haleakalā, never expect-
saber-toothed tiger ference room, it seemed clear that
one of the most opportune moments
ing that anyone would smell the hau musk or Neandertal in DNA’s four-billion-year career had
kuahiwi again. From there, the genes’ begun. This novel environment of
unlikely journey along Resurrection hemoglobin out bioengineering labs and digital data-
Road had taken them to the College of
Hawaii’s herbarium, where the plant
of cells. bases and DNA printers was giving
genes a newfound freedom to flow,
was dried and pressed and eventually new ways to replicate, new habitats to
shared with the Harvard Herbaria. There it waited for decades populate, new organisms to seduce. The original form may go
for Agapakis to open its manila folder and break off a piece of extinct, but many functions can return, and at some point—no-
the corpse. The genes were liquefied in Santa Cruz, digitized in body really knows what that is—that resurrection may get an or-
Boston, then reanimated in the tender embrace of an organism ganism to the point of “no longer dead.”
completely unlike the one that hosted their last appearance on As the essential oils saturated the air, the room became an un-
planet Earth. The genes had crossed time and space and out- likely tropical oasis, a hint of smoke in the distance, and it was
ward form, but their information held. easy to imagine the sun-baked lava fields of Haleakalā in the an-
And then it was time to smell them. The Project Cretaceous cient past, a forest of mountain hibiscus all around, bright red
team picked the Hibiscadelphus to go first because its allure was honeycreepers flitting from blossom to blossom. That world will
captivating, much as it had been for many a honeycreeper for mil- never come again, but some of the countless genes from primor-
lennia. On a bright August day in a crisp white conference room, dial Hawaii and other lost landscapes may do just that. They are
the group gathered to sample a variety of formulations—created pressing against the membrane of extinction at this very moment,
for the company by Berlin-based scent artist Sissel Tolaas—that probing, hungry for any chance to get back in the action.
blended the Hawaiian molecules in different combinations and
concentrations. One of the molecules, juniper camphor, was a pric-
ey ingredient in fragrant oils. Hibiscadelphus had expensive tastes. MORE TO EXPLORE
They dipped paper fragrance test strips into 11 elfin bottles, Timing and Causes of Mid-Holocene Mammoth Extinction on St. Paul Island, Alaska.
held them a few inches from their noses and sniffed gently. Team Russell W. Graham et al. in Proceedings of the National Academy of Sciences USA, Vol. 113,
No. 22, pages 9310–9314; August 16, 2016.
members grinned at one another as if they could not quite believe Natural Selection Shaped the Rise and Fall of Passenger Pigeon Genomic Diversity.
they were here. “First resurrected fragrance!” Kelly announced. Gemma G. R. Murray et al. in Science, Vol. 358, pages 951–954; November 17, 2017.
Agapakis’s reaction was more visceral. “I feel overwhelmed,” she IUCN Red List of Threatened Species on Hibiscadelphus wilderianus: www.iucnredlist.org/
said. “I couldn’t imagine what this was going to smell like.” species/30397/9536660
Some samples had flashes of citrus or thyme. All had a woody FROM OUR ARCHIVES
core of bark and juniper that must have been the essence of hau Ancient DNA. Svante Pääbo; November 1993.
kuahiwi. “I like the lightness,” Agapakis said, eyes closed as she
cientificamerican c m ma a ine a
inhaled. “It feels ethereal.”
ENVIRONMENT
Rapid
glacier
retreat
could put
coastlines
underwater
sooner
than
anticipated
Is Antarctica
Collapsing?
By Richard B. Alley
Illustration By Peter Horvath
y´ï¨yĂ3ùU¨D`D¨ where the front edges melt or fall off, to be replaced by that falls on Greenland and Antarctica each year, which
PRECEDING PAGE: GETTY IMAGES (hand, water, buildings)
5ày´`Uy´mïÎ ice flowing from behind. When the loss is faster than the almost entirely comes from the sea, is equal to a layer of
If it does retreat, flow from behind, the leading edge retreats backward, water evaporated from all oceans, just over a quarter of
ïDïĀ¹ù¨m`àyDïy shrinking the ice sheet on land and raising sea level. an inch deep. The ice sheets are now returning about
ÿyàĂ`y`¨å During the 1980s Jakobshavn was among the fastest- 15 percent more than this amount to the oceans, by
ïDïĀ¹ù¨mUàyD§¹ moving glaciers known, racing toward Baffin Bay, even meltwater runoff or icebergs that “calve” off, raising sea
´ï¹ïy¹`yD´Î though it was being held back by an ice shelf—an exten- level a little. If melting remains greater than snowfall
5ĀDïyååïDàïåï¹
sion of the ice floating on top of the sea. In the 1990s for long enough, an ice sheet can disappear. But that
`àù®U¨yjï`¹ù¨m
àDåyåyD¨yÿy¨UĂDå ocean warming of about 1.8 degrees Fahrenheit (one de- could take almost 100,000 years at recent rates. If
®ù`DåÀÀyyï´ gree Celsius) dismantled the ice shelf, and the glacier on warming rises, however, the melting quickens. That is
¦ùåïDyĀmy`DmyåÎ land behind it responded by more than doubling its the case we are facing globally.
Raising
the Global Sea 0 00 00 iles
3'723iÚ'=$7j'=35Öi3%2<=%'75"''!'2232'%5%35
"5?'%525Ý35=53"2%5÷À35%572?jÛ
?5Î Î3$
'35 "Îj%GLOBAL AND PLANETARY CHANGE, <'"Î Àñè
7%÷ĈÀéèÚ37
3"3$%532'235'2?'5=%55%572?2525'0%3"%"2jÛ
? Î Î3$55 "Îj%NATURE, <'"Î Àè %72? j ÷ĈÀéè%572"%<2'%$%5232'7%"Êcutaways)
0 00 00 ilo eters
Small glaciers drain parts of West
Antarctica and can raise sea level a lit-
tle if they melt. But the truly vast gla-
ciers such as Pine Island and Thwaites
pose a much larger threat (main map).
5ÿDîxäääîDßî³î¸î³ç`x¸ÿä³î¸îx
sea as the leading edge recedes inland (illustra-
tions). The broad Bentley Subglacial Trench onne ce el
r
behind Thwaites could allow the glacier to
ns
retreat as far as the Transantarctic Mountains,
which would raise sea level by 11 feet.
nt
ine sl nd
rct
l cier sin
ic
o
re u
eenl rged nt
in
entle u gl ci l renc s
ce s el
w ites
l cier sin
ss c nge 0 3
ounds per s u re oot oss ce el
00 50 0
500 50 0
ilogr s per s u re eter
TERRIBLE BEAUTY and extends about nine times that much below the water. As
AN ICE SHEET’S FLOW depends on how strong the mound is, how these icebergs roll over, they make splashes 50 stories high and
well lubricated it is underneath on land, and whether or not it is earthquakes that can be monitored from the U.S.
held back by a spatula—an attached, floating ice shelf. General at- So far ice-shelf loss and ice-cliff calving are contributing mod-
mospheric warming can soften ice and thaw the places where the erately to sea-level rise. But at Thwaites, this process could make
ice bottom is frozen to the rock below, allowing the ice to slide the rise much more dramatic because a geologic accident has
faster toward the sea. But the heat takes a long time to be con- placed the glacier near a “tipping point” into the great Bentley
ducted through two-mile piles. The big ice sheets have not fin- Subglacial Trench.
ished warming from the rising air temperatures that ended the
most recent ice age more than 10,000 years ago! JUMP THE BUMP
A speedier way to warm the ice and its bed is for water melting ON AN AUTUMN MORNING in 1956, Charles Bentley (who years later
on top to pour down into crevasses. In some places on the flanks would be my Ph.D. adviser) defended his thesis at Columbia Uni-
of Greenland’s ice, meltwater in summer collects in large hollows versity. The next day he hopped a train to Panama, then caught a
on the surface, forming big, beautiful blue lakes. The water, being ship heading south, to be part of the International Geophysical
denser than ice, tends to wedge open crevasses that can reach the Year research project that would analyze planet Earth. He spent
bed at the bottom and drain the lake. An two years in West Antarctica before re-
expanding lake can break through half turning to find that he had not graduat-
a mile of ice or more, creating a flow of ed yet, because his thesis fee had not
water greater than Niagara Falls. In an been paid. In the meantime, he and his
hour, that can warm the bed as much as team traversed more than 3,000 miles
would have occurred over 10,000 years. of ice, to and from the Byrd Station re-
This process is important, and we are search base and across vast reaches of
studying it eagerly. But it is not the great- West Antarctica. (Bentley died at age 87
est worry for people on Earth’s coasts, in 2017.)
because the bumpy bed can also keep the Of the many measurements and dis-
ice from speeding toward the sea. coveries they made, the most important
The same mechanism presents a for our story involved the ice thickness.
stronger threat if it happens on an ice They set off small explosions on the sur-
shelf. In very cold places, the ice flowing face and used seismometers to listen to
into the ocean remains attached but sound traveling through the ice sheet
floating. These ice shelves almost always and bouncing back off the bed. These
occur in protected bays or fjords. The data showed that West Antarctica was
motion of ice shelves is slowed by friction not a thin drape of ice overlying a high
along the shorelines around them and continent, as some had expected. Instead
perhaps with upward protrusions from Bentley and his team found very thick ice,
MELTWATER pours into the Greenland
the seafloor, where the ice locally runs and they discovered the Bentley Subgla-
ice sheet, hastening its slump toward the
aground. The shelf slows the flow of the cial Trench. There the bed plunges more
sea—a sign of things to come in Antarctica.
nonfloating ice on land toward the sea. than a mile and a half below sea level—
Warming air can create lakes on top Earth’s deepest place not under an ocean.
of the ice shelves. When the lakes break through crevasses, a shelf And the ice filling it extends more than a mile above sea level.
can fall apart. For example, the Larsen B Ice Shelf in the Antarctic Bentley and glaciologists who followed him had found a tip-
Peninsula, north of Thwaites, disintegrated almost completely in ping point. The great trench and adjacent basins underlie the vast
a mere five weeks in 2002, with icebergs breaking off and top- center of the West Antarctic Ice Sheet. If the front edge of
pling like dominoes. That did not immediately raise sea level—the Thwaites retreated from the coast back into the trench, it could
shelf was floating already—but the loss of the shelf allowed the ice make an ice face thousands of feet high, extending from far above
sheet on land behind it to flow faster into the ocean—like pulling the trench to deep down into it. Such a cliff—much bigger than at
a spatula away, allowing the batter to run. The ice flowed as much Jakobshavn or anywhere else on Earth—could break fast, making
as six to eight times quicker than it had been moving earlier. For- incredibly tall icebergs that would roll over and float away
tunately, there was not a lot of ice behind the Larsen B Ice Shelf in through the trench outlet to the ocean, raising sea level a lot.
KONRAD STEFFEN, CIRES AND UNIVERSITY OF COLORADO
the narrow Antarctic Peninsula, so it has raised sea level only a lit- Decades of additional research have established just how im-
tle. But the event put society on notice that ice shelves can disinte- portant this mechanism is. John Anderson, who recently retired
grate quickly, releasing the glaciers they had been holding back. after 43 years at Rice University, and many of his graduate stu-
Ice shelves can also be melted from below by warming seawater, dents tirelessly mapped the continental shelf under the ocean
as happened to Jakobshavn. around Antarctica, using side-scan sonar and other tools. During
When shelves are lost, icebergs calve directly from ice-sheet ice ages, Antarctic ice spread many miles farther in all directions
cliffs that face the sea. Although this delights passengers on cruise and withdrew as ice ages ended. The seafloor around Antarctica
ships in Alaska and elsewhere, it speeds up the ice sheet’s demise. today was the bed under the ice sheet in the past. Telltale imprints
At Jakobshavn today, the icebergs calve from a cliff that towers left in seafloor sediments give us accurate stories about ice sheets.
more than 300 feet above the ocean’s edge—a 30-story building— One story is that as expanding ice sheets push forward into the
sea, they drag sediment with them. The ice stabilizes when it a few decades even under fast warming before the collapse of
reaches a local high in the seafloor and then builds the seafloor Thwaites is triggered by loss of its shelf and meltwater widening
higher there by piling the sediment into raised moraine shoals— crevasses. Thwaites then would take a century or so to collapse
long, stony walls that grow where the ice ends. Ice can sit in such completely. They did not know how fast the ice could break,
a position for hundreds or thousands of years, rebuffing weak ef- though, so they set a top rate equal to what Jakobshavn had done
forts to dislodge it. But if enough warming occurs, the ice retreats in Greenland. (It has already exceeded that rate briefly.) And be-
back down the sloping bed into the valley behind the shoal. The cause Thwaites is thicker, it could make much higher cliffs than
ice rarely stabilizes again until it reaches the next high ridge, often Jakobshavn. Higher cliffs tend to break faster (one reason high-
far behind it. Meanwhile icebergs float over the abandoned mo- way engineers leave slopes rather than cliffs). So we could be un-
raine shoal, which is still below sea level, and out into the ocean. derestimating the worst-case scenario, but we really do not know.
This is now happening in many places around Antarctica and This is a good model, but it surely is not the last word from
Greenland. Jakobshavn Glacier has “jumped the bump” of a for- Pollard and DeConto or others. Some hope remains that Thwaites
mer moraine shoal and is retreating back through its valley- could stabilize on a deeper ridge on the downslope of the trench,
shaped fjord, “unzipping” a path into the greater ice sheet. When behind its current position, before retreating still more, for ex-
the first European explorers visited the area that is now Glacier ample. Or icebergs could break off and pile up for a while behind
Bay in Alaska, it was filled with a vast glacier ending on a large the current ridge where the ice now starts to float, helping to re-
moraine shoal. Since then, the ice has retreated from that ridge, or form a shelf that could lessen the ice loss.
bump, more than 60 miles inland to get to the next high ground, To address these and other questions, the National Science
which today is the current shoreline of the beautiful bay. Foundation and the British Antarctic Survey, together with other
Fortunately, most such retreats have only a limited effect on international collaborators, have launched a major effort to learn
global sea level. Even a big Glacier Bay–sized glacier is small com- even more about Thwaites’s history, how the glacier is flowing,
pared with the world ocean. Jakobshavn is just one of dozens of and what the seafloor surface is that it is flowing over, which will
major drainages around Greenland’s ice sheet, but they do not help all of us involved to better predict its future. The data are al-
quickly destabilize their neighbors in adjacent fjords, and they most guaranteed to reduce uncertainties and to be fascinating.
end not too far inland where the bed rises again. Similarly, Ant- Some questions may remain difficult to answer. Think of all
arctica is drained by a great number of glaciers flowing down into the ceramic coffee cups you have seen dropped on a hard floor.
their own waffle-iron valleys. With enough warming, many of Some bounce, some crack, some chip, some break into a million
them might retreat in unison, but each by itself is not a huge influ- pieces. The physical processes of these fractures are well known
ence on the global sea. and readily calculated, and the behavior averaged across many
The Bentley trench in West Antarctica and a few other deep re- dropped cups is predictable. But you would not want to bet your
gions in East Antarctica, including the Wilkes and Aurora basins, career, or anything else important, predicting the fate of the next
present a different story. Retreat through one of these to the next cup that hits the floor.
high ground would have global importance. Models point to The future of Thwaites depends a lot on fractures. Will the ice
Thwaites Glacier as the most likely path into the Bentley trench shelf fracture from the ice that now feeds it, causing the ice sheet
and connecting basins. If it started unzipping into the interior as to jump the bump and retreat into the deep basins? Will huge ice-
Jakobshavn has, the melting could potentially raise sea level 11 bergs break off rapidly if ice-shelf loss produces a cliff along the
feet before it stabilizes on high ground on the other side of the sheet’s face that is higher than any now on Earth, driving retreat
trench. The East Antarctic basins by themselves could raise sea faster than any we have seen? Meltwater is important, but how
level more than Thwaites would, but they require more warming much of the water will run off in rivers to the sea, and how much
to cause those glaciers to jump their bumps. will percolate into snow and refreeze? How fast will the air warm?
Note that there is nothing bizarre about this scenario. With I suspect that coffee cups are easy to predict in comparison.
sufficient warming, ice retreats, usually to the next high ground. If the world can muster the effort, slowing and stopping warm-
This has been observed over and over in the past and present. If ing from greenhouse gas emissions will slow sea-level rise, easing
Thwaites becomes warm enough to start acting like ice in Green- the mounting costs of coastal damage. But if Thwaites is poised to
land and Alaska, then it should retreat. retreat briskly, preventing warming by limiting the damage in-
curred by human activity could be vastly more valuable.
A FRACTURED FUTURE?
HOW FAST COULD THWAITES GO? How much warming can we cause
before it goes there? MORE TO EXPLORE
My colleagues David Pollard of Pennsylvania State University Oceanic Forcing of Ice-Sheet Retreat: West Antarctica and More. 2`Dàm
Ψ¨yĂ
and Robert M. DeConto of the University of Massachusetts Am- yïD¨Î´Annual Review of Earth and Planetary Sciences, <¹¨ÎñjÈDyå÷Ĉé÷ñÀè$DĂ÷ĈÀÎ
Contribution of Antarctica to Past and Future Sea-Level Rise. 2¹Uyàï$Îy¹´ï¹D´m
herst programmed an ice-flow model that uses the relevant phys- Dÿm0¹¨¨Dàm´Nature, <¹¨ÎñÀjÈDyåµÀµéè$Dà`ñÀj÷ĈÀêÎ
ics and can be run fast enough on advanced computers to study How Much, How Fast?: A Science Review and Outlook for Research on the
big changes in ice sheets over long times. I helped them a little Instability of Antarctica’s Thwaites Glacier in the 21st Century. 5ÎÎ3`D®U¹åyïD¨Î
with the physics of calving from high cliffs after ice shelves break ´Global and Planetary Change, <¹¨ÎÀñjÈDyåÀêñè ù´y÷ĈÀéÎ
off, especially if surface meltwater wedges open crevasses. FROM OUR ARCHIVES
Pollard and DeConto optimized this model to match data from Witness to an Antarctic Meltdown. ¹ù¨Då¹āè ù¨Ă÷ĈÀ÷Î
the geologic past and to assess the impacts of different amounts of
cientificamerican c m ma a ine a
human-caused warming. They determined that we probably have
GUARDIANS
of the
TIGER
PEOPLE As anthropologists debate how best to
protect uncontacted tribes, indigenous
groups in Colombia are working
to shield their isolated neighbors
from the march of modernity
By Adam Piore
Photographs by Juan Arredondo
J
JHONATTAN ANDRES PEREA SQUINTS THROUGH Adam Piore is a freelance journalist. His last article
for I Y_[dj_ÒY7c[h_YWd examined the movement to
the blinding Amazonian sunlight into a wall bring evolution back to the classroom.
of jungle. He steers the tiny motor powering
his wood longboat through a tributary of
Colombia’s mighty Caquetá River and putters
up to a muddy bank. Hopping onto a barely 1
discernible path, the twentysomething
member of the Carijona tribe beckons five
others, including me, to follow. Then he
disappears into the green, amid a cacophony
of unseen birds, monkeys and insects. The
vegetation is so dense and the dark, musty path
so twisting that for a few moments, it seems
to those of us behind Perea that the jungle has
swallowed our young guide whole. Until we
emerge from the trees a few minutes later to
find him standing before a shimmering salt
lake. Perea is gazing intently into the distance.
“This is as far as we are allowed to go,” he says.
“There’s a swampland beyond this. According
to legend, that swampland divides us physically
and spiritually.” Then he points solemnly across
the lake. “That way,” he says. Somewhere out
modern Western world reached this remote area. The legends
there. “That is where they are.” tell of a clan of fierce warriors who painted stripes on their bod-
ies, pierced their noses and ate their enemies before fleeing
“They” are the mysterious tribespeople who reside as close as down a Caquetá tributary called the Bernardo River into the wil-
six miles from the invisible boundary that marks the beginning derness around the 19th century to escape the white man. The
of their territory here in the Curare–Los Ingleses Indigenous Carijona and the 14 other tribes that inhabit the lands that bor-
Reserve in southeastern Colombia. Unlike the Carijona and the der the territory of the uncontacted group regard their isolated
other tribes that live on the periphery of this territory, which neighbors with a mixture of awe and fear; they envy the purity of
extends into the neighboring Río Puré National Natural Park the tribe’s culture and believe its shamans to be so close to
and other areas, this enigmatic group has had virtually no expo- nature that they can control the elements.
sure to modern civilization. Indeed, it has actively sought to Nobody knows how many of these secluded people now re-
avoid any contact with the outside world. Its members survive side in this jungle sanctuary—estimates range from 50 to 500.
much as they have for millennia, naked in the jungle, hunting But encroachment by outsiders would threaten their way of life—
with poison-tipped arrows and blow darts, using stone axes to in fact, their very existence. Perea and his peers are working to
fell trees and bamboo knives to cut their food. prevent intrusion. I have come to Curare to see how they are
Some of Perea’s tribe call these men and women “our broth- helping their uncontacted neighbors maintain their solitude in
ers living in a natural state.” Other locals call them the “Tiger an increasingly connected world.
People.” (There are no tigers in South America, but the word Anthropologists, activists and government officials have long
tigre is sometimes used to refer to local jaguars.) It is a nick- debated how best to protect such uncontacted tribes in the
name passed down through the generations from a time before Amazon and elsewhere. Because they have been living in isola-
the missionaries, the rubber barons and all the trappings of the tion, they have little or no immunity to diseases common among
IN BRIEF
An estimated 100 tribes around the world live in Scholars and policy makers have long debated how Their work could pave the way for safeguarding
isolation. Contact with outsiders can be disastrous, to protect these uncontacted groups. In Colombia, perhaps as many as 17 other uncontacted tribes that
often exposing them to deadly pathogens. indigenous people are defending their neighbors. are thought to live in the Colombian Amazon.
armed, evil actors who covet virgin timber, gold and other áR Curare-Los Ingleses
et
iver
natural resources often hidden in their lands. Indigenous Reserve
In 2012 Perea’s tribe and the other communities of Curare,
ECUADOR
along with groups in other nearby areas, launched an aggres-
sive effort to patrol the borders and protect the lands of their Río Puré National
ona Natural Park Puerto Franco
uncontacted counterparts from incursions of loggers, hunters,
gold miners, missionaries, smugglers, drug dealers and com-
munist insurgents. Recently their mission has taken on added PERU BRAZIL
urgency. For decades Colombia’s civil war stalled development
in the Amazon, and the presence of insurgent camps, right-
Yet as remote as Curare is, life here in the borderland is none- engine Cessna. On the first day they spotted a longhouse sur-
theless shot through with elements of modernity. Many of the rounded by fruit trees—and snapped photographs of an indige-
children attend a boarding school across the river from La Pedre- nous tribeswoman, her face and body painted, who could clear-
ra that was run by Catholic priests until last year, when the gov- ly be seen gazing up at the plane. The footage, along with the
ernment took it over. Tribespeople regularly travel to La Pedrera identification of four other malocas, was enough to get the gov-
for modern health care and to more distant cities such as Leticia ernment and the nation’s indigenous groups to agree to begin
and even Bogotá when they have a serious illness or a broken the process of hammering out protections for the nation’s isolat-
bone. Many wear modern clothing and use machetes, flashlights ed peoples.
and steel pots purchased in towns such as La Pedrera and have In 2014 Franco was flying home from another community
been exposed to television. It is a testament to the determination farther north when his aircraft went down, killing all 10 people
of the uncontacted tribespeople and their self-appointed guard- onboard—including Daniel Matapí, another ACT staff member.
ians that these influences have not reached the interior. It was a devastating blow for ACT and for Aristizabal, then a
The indigenous people in Curare and Río Puré have known young Ministry of Interior official, whose graduate thesis
for generations of the presence of their mysterious brethren in focused on preserving the privacy of isolated tribes. Aristizabal
the interior, believed by scholars to be members of two related had been closely collaborating with Franco to develop new laws
tribes called the Yuri and Passé. But it was the arrival of a Colom- to that end. After Franco’s untimely death, Aristizabal agreed to
bian environmentalist named Roberto Franco and ACT in the join ACT and continue his legacy.
early 2000s that would thrust them into the center of Colom-
bia’s dialogue over how to defend its most isolated peoples. A CENTRAL TENET of that legacy has been partnering with the
Franco, the author of numerous books on the history of the indigenous groups in Curare to support their protection efforts.
Amazon, was for years one of the leading Colombian proponents While I was in Curare, the communities were holding their an-
of the idea that the best way to protect the rain forests was to nual meeting to review those efforts and plan for the year ahead.
uphold the land rights of the nation’s indigenous tribes, whose Aristizabal and I made our way to an enormous maloca with a
cultures were based on living in harmony with their surround- 30-foot-high thatched-palm roof to join them.
ings. He had also worked as an anthropological consultant to Once inside, Aristizabal and I were greeted like old friends.
government agencies, had seen the ravages of first contact first- In the center of the structure, eight male community elders
hand and had come to believe that “self-isolation” was a human- dressed in soccer shirts and T-shirts were clustered together on
rights issue. Intent on finding a way to shield the nation’s most their ritual wood benches. As they chatted and laughed, they
vulnerable groups, Franco began collecting
scraps of information about isolated peoples
during his expeditions through the Amazon
in the 1980s. He scoured the historical litera-
e t n er in an rain
ture for clues, pored over maps and conduct-
ed interviews—even meeting with former
ere a me a e fr m t e i er
rebel commanders and drug traffickers who
had come across uncontacted tribespeople in
e e a in ea e a ne
their travels through the bush. —Alfonso Matapí, shaman
To win official government protection, how-
ever, Franco needed concrete proof of the ex-
istence of these tribes. In 2007 ACT agreed to support his efforts passed around tall, cylindrical Tupperware containers of mam-
to get it. By then Franco had already decided that Curare and be, a mixture of coca leaves and ash, copious amounts of which
Río Puré were the most promising places to start. In the late they shoveled into the space between their lips and gums with
1960s a rubber tapper and fur trader named Julian Gil came metal spoons. Around them, children chased one another, trip-
across a well-worn path deep in the jungle, far from any settle- ping and laughing, as their parents watched from long planks
ment, and followed it to a vast longhouse, or maloca, where he arrayed between the pillars holding up the structure. Others
discovered scores of tribesmen in the middle of a celebration. reclined in hammocks slung to the far walls.
They wore nothing but tiny pouches covering their privates and Over the next three nights, various tribal figures would step
sticks as thick as pencils through piercings in their ears and nos- across the hard-packed earth to the front of the maloca to deliv-
es. They had painted their bodies in stripes. But the tribe wanted er reports on a wide range of activities, conducted over the pre-
nothing to do with the visitors, and the meeting turned violent, vious year, aimed at securing the reserve and its inhabitants.
resulting in the disappearance of Gil and the deaths of a number The proceedings were unhurried and deliberate, offering ample
of tribesmen. The Colombian military took several tribe mem- opportunity to reflect on the challenges facing both the uncon-
bers prisoner, prompting a worldwide outcry. The military subse- tacted peoples and their guardians.
quently freed the prisoners and vowed to leave the tribe in peace. Some participants spoke about preserving the cultural tradi-
These people are believed to have been members of the Yuri tions of the tribes that do have contact with the world beyond.
and Passé tribes, groups that began fleeing white slavers hun- One young tribesman described his efforts to make story books
dreds of years ago, settled in the area and were thought to have for the smallest children detailing the traditional legends that
gone extinct. But in 2010 Franco and a small crew flew over the would help explain the importance of the protection of sacred
most likely habitation zones in Curare and Río Puré in a single- places and the reserve management plan. “As you know, the sto-
ries of the elders are very, very long. For example, the origins of From the east, illegal gold-mining barges, crossing in from
animals and the origin of crops,” he noted. “So we listened to all Brazil, are a constant concern. Drug traffickers and bandits,
the stories, and part of the challenge was to summarize them.” meanwhile, have made intermittent appearances in some areas
The report was followed by a chorus of low, deep-throated mm- of Curare itself—and some fear their presence might actually
hmms from the elders and the rest of the maloca, a traditional increase as the insurgent demobilization progresses. In 2016
way of showing their appreciation or support for a point. members of a dissident faction of the Revolutionary Armed
Other speakers raised the issue of sustainability of the re- Forces of Colombia (FARC), unhappy with the peace accords,
serve’s flora and fauna. When a tribal elder reported on the re- entered the reserve. Toting their weapons and slogans, they
sults of an investigation into the illegal killing of a pregnant convinced the teenage son of a Curare community elder to run
tapir in an area where the tribe had restricted hunting, an angry away with them.
debate broke out over how large a fine or how much volunteer To monitor these threats and help respond to them, ACT
work to impose on the guilty parties as a penalty. staffers supplement the tribal on-the-ground patrols with mod-
Eventually the topic turned to the battle to keep interlopers ern technology. From offices in Bogotá and Virginia, ACT staff-
out of the reserve. Even without development, the threats to the ers comb through reams of satellite imagery, searching for signs
location and the isolated tribespeople that live there are many. In of illegal barges and deforestation while looking for isolated
2015, before the peace accords, Colombian authorities intercept- tribal dwellings. (The images are provided free of charge by U.S.
ed two American evangelical missionaries south of Río Puré who commercial satellite provider DigitalGlobe, and the quality and
were attempting to contact and convert the isolated tribes to resolution improve by the year: it is now at 30 centimeters, clear
Christianity, seemingly indifferent to the danger that contact enough to examine a banana leaf from space.)
might pose to their targets—and to themselves. ACT staffers also confer regularly with partners in the Na-
for a shaman from a community three days upriver in a neigh- the land rights and protections conferred on isolated tribes as con-
boring national park. firmation of their existence moves from suspected to confirmed.
The shaman, Alfonso Matapí, age 78, says that when he arrived, The document also requires contingency planning in case of first
he quickly realized that the locals were out of sync with the nat- contact and creates a national committee for coordination that
ural elements of the jungle and had angered the far more power- would include indigenous leaders and representatives from the
ful medicine men of the Tiger People. Franco’s plane, he opines, national land agency treasury, ministries of environment, health
“came down not because of a malfunction but because the tribes and interior, and armed services, among others.
didn’t want the flights. There were many flights. And they made For his part, Aristizabal is under no illusions as to the size of
his plane crash.” (The others onboard were innocent victims.) the challenges that he faces. If anyone needed a reminder, cer-
The guard perished because he entered forbidden lands near the tain events of late have provided plenty. Recently a dissident
sacred salt lake; the animals that rely on the lake fought back. FARC faction was back in the area. One group found the wife of
“The thunder, wind and rain were [a message from the Tiger a prominent local leader and village elder whom I met during
People] saying, ‘Leave us alone,’ ” Matapí explains. “So I try to my visit and threatened to kill him and his family if he did not
send them thoughts saying, ‘Don’t worry, we’re going to leave stop speaking out about indigenous land rights. Yet Aristizabal
you alone. Don’t worry, we’re not going to bother you.’ ” remains firm in his belief that shielding isolated tribes from con-
tact is the best thing to do. “Of course, it is very difficult to pro-
IT IS POSSIBLE, of course, that the isolated tribes will initiate con- tect someone from contact forever,” he says. “But that doesn’t
tact with their neighbors in the borderland. To help prepare mean that we shouldn’t respect their desire to avoid contact.
the residents of Curare for such an event, ACT and community Why should we make the decision for them?”
members have consulted with groups and individuals who In recent months ACT has continued to try to gather the proof
have experience with uncontacted tribes. Among them is Luis it needs to expand its efforts to other tribes. Not long ago it had a
potential breakthrough in the region up the
Caquetá where Franco perished. For five years
Ùîäþxßāl`ø§îî¸Ç߸îx`î
ACT members had been combing through
high-resolution photographs, searching for
evidence of the isolated, indigenous communi-
me ne fr m c ntact f re er ty believed to live in Chiribiquete National
A A S
THE EXOPLANET
What Venus can teach us about planets
far beyond our own solar system
By M. Darby Dyar, Suzanne E. Smrekar and Stephen R. Kane
NEXT DOOR
A A A A fr m t e a e an
acecraft a e t create t i
c m ter enerate ie f en
at na r na an ai a ma
N 1982 ALL ANYONE COULD TALK ABOUT IN THE PLANETARY SCIENCE DEPARTMENT AT THE
Massachusetts Institute of Technology was the cancellation of NASA’s latest flagship mis-
sion, the Venus Orbital Imaging Radar (VOIR). One of us (Dyar) was a graduate student
there at the time. (The other two were still in college and elementary school.) Graduate
students wept openly in the hallways, and veteran faculty shook their heads. The newly
elected Reagan administration had enacted sweeping cuts to space exploration, and VOIR
was one of the casualties.
Shortly afterward, though, scientists cobbled to- main the foundation of Venus geoscience to this day.
gether plans for a bargain-priced spacecraft ($680 But planetary scientists never give up, and we have
million) made of leftover hardware and, miraculously, made progress in uncovering the secrets of this world
saved the mission. In 1989 the Magellan orbiter launched nonetheless. Since Magellan, the European and Japa-
on a reconnaissance mission to Venus, and by 1990 it nese space agencies have sent successful missions to
was in orbit. Over the next five years the orbiter Venus, leading to breakthroughs in understanding its
returned near-global radar images, gravity data and a atmosphere. Meanwhile scientists have been busy
topographic map of the second planet from the sun. It rewriting the textbooks on our sister planet by per-
was the latest in a long line of Soviet and U.S. missions forming new analyses of Magellan data. We now think
to our neighboring planet, but when Magellan that volcanoes are rampant on Venus, and we have
plunged to Venus’s surface in 1994, NASA’s support for even found hints of the start of plate tectonics, which
Venus spacecraft died with it. Since then, scientists scientists think is critical for a planet’s habitability.
have submitted more than 25 proposals for return New theoretical models also suggest Venus may have
missions to Venus, and although some of those had liquid water on its surface until relatively late in
received high rankings from review boards, none were its history—meaning that it may have been hospitable
approved. Decades-old data gathered by Magellan re- to life much longer than we once thought.
PRECEDING PAGES: NASA AND JPL
IN BRIEF
Venus and Earth started out much the same, Venus’s surface, meanwhile, became inhospitable Learning why Venus evolved the way it did could illu-
but at some point, the planets diverged. Earth to life. Yet our neighboring planet still has active minate the possibilities for life on the many Venus-like
went on to host oceans and an atmosphere. volcanism and hints of nascent plate tectonics. exoplanets out there. A new mission to Venus is needed.
All of this coincides with another stunning devel- stars for telltale brightness fluctuations that occur as VENUS’S
opment in astronomy: the discovery of thousands of orbiting worlds pass in front of them. With this tech- ATMOSPHERE,
exoplanets in other solar systems, many of them nique, we can measure a distant planet’s size, but size as seen in
roughly the same size and distance from their stars as tells us only so much. After all, if an extraterrestrial this composite
Venus. Anything we learn about the planet next door observer were to look at our solar system using the image from
could teach us about these distant, inaccessible worlds. transit method, Venus and Earth would appear almost data taken by
In particular, if we can figure out whether and when identical. Yet Venus is forbidding to life, whereas Japan’s Akatsuki
Venus may have had the conditions to host life, we will Earth has been continually habitable for the past four spacecraft,
JAXA, ISAS, DARTS AND DAMIA BOUIC
know more about the likelihood of finding living billion years. contains thick
beings on the plethora of Venus-like bodies through- We can further differentiate between similarly sized clouds of
out the Milky Way. planets by measuring their distances from their stars. sulfuric acid.
The “habitable zone” is the region around a star where
A A A a rocky planet could have liquid water on its surface.
MOST OF THE EXOPLANETS discovered so far were found Earth, obviously, is in this zone. Venus, we think, used
using the transit method, in which astronomers watch to be in this zone—for quite a while, in fact. Yet the
boundaries of the habitable zone move outward with water by dissociating it into hydrogen and oxygen ions
time as the sun’s luminosity increases with age. Venus and carrying them off into space. Without surface
is now outside this range and occupies what we call water to dissolve the carbon dioxide and other gases
the “Venus zone,” where surface conditions are so hot constantly escaping from the interior, these chemicals
that a planet is likely to have a runaway greenhouse accumulated in the atmosphere. Because of the green-
atmosphere that would boil its oceans away. house effect of this atmosphere, surface temperatures
Venus and Earth formed under very similar condi- on Venus are nearly 800 degrees Fahrenheit higher
tions—including those that gave Earth its oceans. than on Earth—hot enough to make rocks glow.
Comet impacts probably brought ice to the surface of The only data we have from the surface of Venus
both planets. The solar wind (charged particles gush- were collected by the four Soviet Venera landers that
ing off the sun) most likely implanted a thin layer of touched down in the 1970s and 1980s. These probes
hydrogen ions on the surfaces of both. And when survived for only a few minutes on the planet’s brutal
Venus and Earth were protoplanets building up from surface, but in that brief time they gathered and sent
the primordial dust disk that circled the sun, both col- back rough measurements of the chemical composi-
lected hydrogen and other volatiles, chemicals that tion there. Beyond those readings, our knowledge of
the surface mineralogy rests solely on controversial
interpretations of radar measurements made by
mission to the oft- these windows coincide with critical regions for iden-
tifying the typical planetary minerals olivine and
planet from the sun. 2014, used one of these windows to produce the first
map of heat radiating from the planet’s surface over
much of the southern hemisphere. This map includes
spectral features—peaks and dips in light and heat—
can easily boil away. Simulations of early Venus show that can identify minerals on the ground.
that the planet’s surface may have had liquid water The map also identifies many hotspots—areas emit-
earlier than Earth and that water might have been ting so much heat that the most likely explanation is
there until about a billion years ago. recent volcanism. This is an exciting find because it
The fact remains, though, that Venus is now for- shows that unlike the moon, which has long been
biddingly inhospitable. What happened? Does Venus silent, and Mars, where modern volcanism has been
represent the end state for all habitable planets, or is isolated at best, Venus is still active—and that discov-
it merely one of many ways that planets of this size ery has implications for the planet’s suitability for life.
can turn out? These are some of the major questions
we want to go back to Venus to answer. A S
ON EARTH, volcanism is usually associated with plate
S S A tectonics—the shifting and sliding of large pieces of
OUR KNOWLEDGE OF VENUS is limited in part by the crust responsible for most of the geologic features on
immense difficulty of seeing through the planet’s our planet. Plate tectonics is also behind the long-
thick, noxious atmosphere. High up, clouds of sulfuric term climate cycles, occurring over periods of around
acid shroud the world. On the ground, the air pres- 100 million years, that enabled life to arise on Earth.
sure is comparable to the water pressure 3,000 feet Plate tectonics formed new crust at Earth’s mid-ocean
below the surface of Earth’s oceans. The atmosphere ridges and allowed layers of its crust to sink into the
there is so dense that its main constituent, carbon mantle—two processes that enabled our planet to lose
dioxide, acts as a supercritical fluid, with properties its internal heat and cool to a point where life could
midway between a gas and a liquid. arise. Tectonics also released volatile chemicals such
Scientists think this atmosphere was once Earth- as water, carbon dioxide and sulfur dioxide from deep
like. Unlike our world, though, Venus now lacks a within Earth out into the atmosphere and cycled vola-
magnetic field to repel the solar wind. We think that tiles back into the mantle when plates slipped under-
over the eons, the solar wind eliminated the planet’s neath other plates.
Planetary Comparisons
at ma e a anet a ita e This is one of the biggest plate tectonics and other conditions on Venus, scientists hope
questions in astronomy. Earth and Venus started out quite to understand why the planet evolved as it did and whether it
similar, but one is now a bastion of life and the other an inhos- can teach us about the prospects for life on the many Venus-
pitable wasteland. By studying the development of volcanism, like exoplanets throughout the Milky Way.
LIQUID SURFACE
WATER PRESENT
3 billion years ago
Water, the key ingredient for life,
was present inside the building
blocks of planets and was re-
leased to the surface via volcan-
ism, with lesser contributions
from cometary impacts. Aside
from Earth, Venus most likely
held onto its oceans the longest.
2 billion years ago
CONDITIONS
FAVORABLE TO
DNA-BASED LIFE
Scientists can only speculate on
when and how long each planet
had the necessary ingredients
1 billion years ago to host life. But researchers have
reason to believe Venus became
a habitable world before Earth and
spent more than a billion years
with the conditions needed for life.
Today
HABITABLE ZONE
This region is the area around a star
where planets could sustain liquid
water and thus potential life.
Because the sun has grown more
luminous over time, the boundaries
Sun of the habitable zone in the solar
system have shifted outward.
Habitable Zone
1 billion years ago
Sun and planets
not drawn to scale Astronomical units: 0.5 1.0 1.5 Today
tions show no evidence of interconnected plates— can answer compelling questions about volcanism
rather we see isolated spots where subduction is and possible plate tectonics at Venus. Is the process
beginning, in each case around one of these circular truly occurring now? How do the surface activities
regions where plumes appear to be rising up. Two relate to what is happening in the planet’s interior?
How do the conditions on Venus, such as its tempera- the generation of scientists who launched Magellan is
ture, affect this tectonic activity? And are some sur- growing old and retiring. A mission to Venus now
face features we see, such as the crinkles scientists call would allow researchers to pass the torch to a new
tesserae, remnants of a past, wet epoch? generation who can bring us closer to understanding
In 2019 NASA will solicit proposals for the next why our planetary sister evolved so differently from
group of its smallest class of space probes, called Dis- Earth. Perhaps we may even discover what conditions
covery missions. Another of us (Smrekar) and Dyar are necessary for the emergence of life.
are leading one proposed mission called VERITAS
(Venus Emissivity, Radio Science, InSAR, Topography,
and Spectroscopy), which would map the surface in MORE TO EXPLORE
much greater detail than ever before. It would carry Was Venus the First Habitable World of Our Solar System? M. J. Way et al. in Geophysical Research
several instruments, including an imaging camera Letters, Vol. 43, No. 16, pages 8376–8383; August 28, 2016.
and spectrometer, to provide orders-of-magnitude- Experimental and Observational Evidence for Plume-Induced Subduction on Venus. A. Davaille
level improvements in topography resolution and the in Nature Geoscience, Vol. 10, pages 349–355; May 2017.
first-of-its-kind global composition map of the planet. FROM OUR ARCHIVES
Other Venus mission proposals are also in the works, Global Climate Change on Venus. Mark A. Bullock and David H. Grinspoon; March 1999.
and we should find out the final results in 2021.
cientificamerican c m ma a ine a
Nearly 30 years after Magellan arrived at Venus,
e
x³w³xxß
t ew³
¸§¸ßDl¸
wþxß
Can dam releases that mimic natural flows
restore the Grand Canyon ecosystem?
By Heather Hansman
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
A A ³ßą¸³D
`ßxDîxäāl߸ǸÿxßUā`¸³î߸§§³
ßx§xDäxä
߸"D¦x0¸ÿx§§jîxäx`¸³l
§Dßxäîßxäxßþ¸ß³îx7Í3Í
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
IN BRIEF
Nearly 40 million people rely on the Colorado In 2018 researchers tested consistent dam releases But as the result of climate change, decreased
2ÿyà¹àĀDïyàD´mȹĀyàjD´mïå¹Āåy´ that allowed the river to run more “naturally.” They snowfall and increased evaporation mean there is
neered to maximize those resources. But the ever DàyïàĂ´ï¹ù´myàåïD´m¹Āï¹Uà´UD`§´Dïÿy ¨yååĀDïyàDÿD¨DU¨y¹àyāÈyà®y´ïD¨¹ĀåÎå´yĀ
`D´´ày¨yDåyå๮ïy¨y´D´Ă¹´D® insect populations—and restore ecosystem àyåyDà`´¹à®å®D´Dy®y´ï¹ïy¹¨¹àDm¹2ÿyàj
have harmed the Grand Canyon ecosystem. yD¨ïĀï¹ùïmåàùÈï´y´yàĂÈà¹mù`ï¹´Î ïyĀyåïyà´7Î3ÎåÈàyÈDà´¹àĀDïyà`ùïUD`§åÎ
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
another. “You can’t pull one string and not expect it to change,”
Kennedy says. So, in 1995, as part of the AMP, the U.S. Geological
Survey created the Grand Canyon Monitoring and Research Cen-
ter to investigate those impacts and serve as the sole science voice
ME ICO among its powerful group.
Under the aegis of the USGS, the geologists, hydrologists, biol-
ogists, ecologists and other scientists of the GCMRC monitor the
river and advise the AMP. During the past two decades the
The insect research is a meaningful step toward sustaining the researchers have built a longitudinal data set to establish a base-
river for habitat as well as for humans. It also runs straight into a line of life in the canyon. They devised experiments to explore
core conflict between science and Colorado River policy: scien- declining fish populations and disappearing sandbars—all, ide-
tists want the flexibility to experiment, whereas power and water ally, without cutting into the needs of the other stakeholders.
managers want stability. As the Colorado dries up, this conflict “Nobody had done ecosystem science and looked at the manage-
will intensify. And yet if Kennedy and others can show that chang- ment of a dam before,” says Dave Wegner, a former Bureau of
ing the flow can bring back insect populations, it could make eco- Reclamation ecologist who set up the GCMRC at its outset. “We
system health a bigger priority for those who manage the most were making it up as we went.”
used river in the West. It is easier to flexibly manage an ecosystem in the single-spe-
cies fisheries where adaptive management was first conceived. In
A a nonlinear system as complex as the Colorado River, this iterative
AS SOON AS THE PENSTOCKS CLOSED on the Glen Canyon Dam in 1966, strategy is also a tension point—especially when any tweaks re-
it became clear that the fragile, federally protected downstream quire consensus among 25 competing values. “We change some-
ecosystem of the Grand Canyon National Park was unexpectedly thing we can control, and then two things we can’t control very
altered. Inconsistent, sediment-depleted flows scoured sandbars, quickly change,” says geologist Ted Melis, deputy director of the
a significant habitat structure for native plants such as coyote Southwest Biological Science Center, which oversees the GCMRC.
willow and arrowweed. The clear, 48-degree water, released from For instance, the GCMRC is currently trying to unpack a 1,000 per-
the depths of Lake Powell, stressed endangered fish, which cent increase in populations of predatory, nonnative brown trout
were adapted to silty, 80-degree flows. Very little was known since 2012. The spike happened around the same time as experi-
about the interconnectedness of such elements before the dam mental high flows that were designed to build sandbars. But that
was constructed, so these changes came about without fore- is the point of adaptive management, Melis says: learning from
thought for the consequences. the ecosystem shifts and responding to them.
It was not until 1989, after scientific evidence from an initial
1982 assessment and under pressure from both the public and "''!5'5
73
agencies such as the National Park Service, that the secretary of IN NOVEMBER 2017, several months before the weekend bug flow
the interior asked for the first environmental impact statement experiment began in the Grand Canyon, I joined Muehlbauer and
on the dam. The results, finalized in 1995, confirmed that endan- David Goodenough, another researcher in Kennedy’s lab, to col-
gered species and valuable resources were being affected, but the lect monthly samples of insect populations on the shore and in
Department of the Interior did not have enough data to quantify the river. If the GCMRC scientists can understand what is trig-
how much things were changing. Information found during that gering the bug die-offs, they can explicitly show how factors such
investigation sparked the 1992 Grand Canyon Protection Act, as flow and food webs are related—and why they must be consid-
which required the Bureau of Reclamation to maintain both hy- ered in any management strategy for a rapidly changing future.
dropower and natural habitat while managing the dam. Kennedy has been studying Grand Canyon insects since 2002.
To uphold the act, in 1996 the Bureau of Reclamation formed He thinks that hydropeaking—that is, spiking flows up and down
a federal advisory committee to guide dam operations. Called for power needs—is part of why scientists see minimal numbers of
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
midges and almost no mayflies, stone flies or caddis flies, all of made reservoir behind the Glen Canyon Dam—and divert it to
which are prevalent on other western rivers and were likely once two growing counties in southern Utah. The pipeline was first
abundant on the Colorado. His team modeled how insect egg-lay- proposed in 2006 by the Utah Division of Water Resources, and
ing cycles responded to hydropeaking, and in 2016 the researchers in September 2018 the Federal Energy Regulatory Commission
released a paper hypothesizing that limiting the artificial tides agreed to license the hydroelectric part of the project. As expand-
created by dam releases—for even just two days in a row—would ing communities try to claim every drop of water they are legally
give bugs enough time to reproduce. Now Kennedy and his team allotted, Kennedy is looking at how bugs are tied to the rest of
are racing to test whether adjusting the flow toward a more natu- the river system—and demonstrating how the AMP can manage
ral state will restore and protect the Grand Canyon ecosystem in for both in the face of less water coming downstream.
an increasingly drought-strapped, human-impacted river.
It is only recently that such an experiment could take place. In '552j227572
2016, because both science and statutory responsibilities (such as GIVING SCIENTISTS A VOICE in water management has led to new
additions to the endangered species list) had changed, the insights about how the Colorado River reservoirs are suffering
Bureau of Reclamation and the National Park Service revised the from climate change. Much of the news is alarming. A 2017 study,
original environmental impact statement to allow for a broader published in Water Resources Research, by climate scientists Brad
range of experimental flows. The 2018 bug flow is the first test the Udall of Colorado State University and Jonathan Overpeck, then at
GCMRC has tried within the new legal framework. It is timely the University of Arizona, found that average Colorado River flows
work in the context of a global problem: a 2017 paper in PLOS in the 21st century were 19 percent lower than in the 20th. They
ONE found that in Germany, flying insect populations have plum- predicted flows could drop by up to 55 percent by 2100 as a result
meted by 75 percent since 1990. The authors, led by Caspar A. of the effects of global warming. “If you’ve been paying attention,
Hallmann of Radboud University in the Neth-
erlands, warned this drop would have cascad-
ing impacts on pollination and nutrient cy-
cles across Europe—a scenario already play-
5xä`x³îäîäÿD³îî¸Çßxäx³î
ing out on the Colorado.
On a chilly November dawn, the research-
ßxD丳ä
¸ßDx³l³¸ÿä³îx
ers and I left the GCMRC offices in Flagstaff, ³Dx¸
³DîøßxUx
¸ßxîä
§Dîxî¸Dþ¸lx`¸äāäîx`¸§§DÇäxÍ
Ariz., and drove down to the Lees Ferry boat
ramp, which is 16 miles below the Glen Can-
yon Dam. In a jet boat named Quicksilver,
we zipped up the black glass of the river
toward the dam, then turned downstream into the throat of the especially in the past two or three years, you should be frightened
Grand Canyon. Muehlbauer and Goodenough set four sticky right now,” Udall says, referring to how soon there might not be
traps—back-to-back petri dishes lined with adhesive and glued enough water to meet legal and environmental needs. In the
to aluminum stakes—at monitoring points approximately every Bureau of Reclamation’s yearly water tally, which ends in Septem-
mile to catch adult invertebrates. We passed through 21 miles of ber, the amount of water that flowed into the Colorado River
the canyon, taking drag samples of what is suspended in the Basin in 2018 was only 43 percent of the historical average.
water column to see how bug density and species diversity There is also problematic math at Lake Powell. Because the
changed the farther we got from the dam. Colorado’s water is allocated down to virtually the last drop, the
There were almost no bugs on the river. None in our teeth or lake level is crucial to a 1922 legal compact that guarantees 8.23
our eyes as we motored downstream. Nothing biting when we million acre-feet of water will flow past Lees Ferry every year.
pulled up in tamarisk bushes to collect the sticky traps. When The Bureau of Reclamation built reservoirs—including Powell—
Muehlbauer pulled a sample stake and looked inside the petri starting in the 1950s. But these storage systems only work if they
dish, he was underwhelmed. “Oh, my God, David,” he said, roll- are replenished. Lake Powell is considered “full” at 3,700 feet
ing his eyes at Goodenough. “We caught . . . midges!” above sea level; the last time that happened was 1986. In 2002,
Later, they sorted through the samples in the lab, pulling out the driest year on record, only 3.8 million acre-feet flowed into
chironomine bodies with tweezers and tallying the different spe- Powell from upstream on the Colorado. Because Lake Powell’s
cies, painstakingly adding to a 22-year record of the individual entire purpose is to keep the downstream water supply consis-
bug totals along the river. Kennedy hopes the data from the con- tent even when it does not rain or snow, the legally obligated 8.23
trolled flows during the summer of 2018 will reveal how the million acre-feet still went out.
physical processes of dam releases impact the bugs. The research- This logic, however, is fundamentally flawed. The compact
ers are worried that climate change, among other factors, is water was allocated based on calculations done by the Bureau of
altering conditions faster than they can study them. But if the Reclamation in the early 1900s, the wettest recorded period in
GCMRC can show that engineering the river to run more natu- measured history, which concluded that 18 million acre-feet of
rally makes the entire ecosystem more sustainable, it will empha- water flowed through the river basin every year. Data collected
size the riskiness of new projects that threaten to divert even from USGS river gauges installed at Lees Ferry in 1922 have
more water from the Colorado. showed that average yearly flows are actually 14.8 million.
Take the Lake Powell Pipeline, for example. It would remove Because the compact is federal law, the 8.23 million acre-feet of
86,249 acre-feet of water every year from Lake Powell—the man- downstream obligations still stand. Water managers call this a
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
rivers to provide utilitarian benefits,” he says. Areas. Caspar A. Hallmann et al. in PLOS ONE, <¹¨ÎÀ÷j%¹ÎÀĈjàï`¨y%¹ÎyĈÀ~~Ĉµè
'`ï¹UyàÀ~j÷ĈÀéÎ
2%5'05 FROM OUR ARCHIVES
AS AN IMPENDING WATER CRISIS DAWNS, the GCMRC scientists are try- Change of State. D´
Dù®èùùåï÷ĈÀÎ
ing to experiment as much as possible. They want to present con-
ä ` x ³ î
` D x ß ` D ³ Í ` ¸ ê D D ą ³ x êä D
crete reasons for amending flows in the name of nature before it is
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
OUTLOOK
GENE
THERAPY
Herbert Medina Iman Jilani Adekunle Onadipe Guoyun Bai Ricky Fernandes Sonal Bhatia
Everything that makes us unique makes us uniquely good at the work we do together.
Farhan Hameed Elaine Ravasco Adekola Alagbe Kelly Voight Patrick McCann Karen Walters
W masterclasses.nature.com
Follow us on LinkedIn
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
OUTLOOK
GENE THERAPY
P
OUTLOOK 13 December 2018
Supplement to Nature
Research journals
harmaceuticals cannot always fix a malfunctioning
human body. Sometimes the only way to treat what ails CONTENTS
GENE
THERAPY
a person is to tinker with their genes: the blueprints
for how biological systems are built and how they operate. S4 NEONATOLOGY
Some researchers are using gene-editing techniques such The fix is in utero
as CRISPR to precisely alter DNA sequences. Others are Hereditary diseases healed prenatally
genetically modifying immune cells to imbue them with S7 PERSPECTIVE
Revolutionary
A genetically augmented future
Produced with support from:
repairs
the ability to fight cancer. And in the past couple of years,
Ellen Wright Clayton on medical ethics
Cover art: Sam Falconer there has been a rapid acceleration in the development of a
wide range of treatments in which disease-causing genes are S8 NEUROLOGY
replaced in their entirety. Repairs for a runaway brain
Editorial
A way to suppress epileptic seizures
Herb Brody, This Outlook therefore focuses on the rich assortment of
Richard Hodson, research in which new genes are introduced into a person, S10 BLOOD DISEASE
Elizabeth Batty, Medicine is in the blood
Lewis Packwood, usually by means of a viral vector (see page S16). Successful Fixing the gene in sickle-cell disease
Nick Haines animal experiments indicate that human genetic disorders
S12 DERMATOLOGY
Art & Design could one day be repaired in the womb, so that a baby might Under the skin
Mohamed Ashour, enter the world disease-free (S4). And a number of health
Wesley Fernandes,
Epidermal cells extracted and repaired
Kate Duncan issues that have proved difficult or impossible to remedy — S14 IMMUNOLOGY
Production such as sickle-cell disease (S10), epilepsy (S8) and certain A genetic shortcut
Nick Bruni, Karl intractable skin conditions (S12) — might be excellent targets How to make an antibody factory
Smart, Ian Pope for gene therapy. S16 THERAPEUTICS
Sponsorship But gene therapy need not be limited to diseases that Special delivery
David Bagshaw,
Jay Berfas,
originate from genetic abnormalities. It might be possible to Making viral vectors more efficient
Anushree Roy treat some viral infections with DNA, by using it to prompt S18 POLICY
Marketing the body into creating just the right monoclonal antibodies to Regulating a revolution
Nicole Jackson ward off invading pathogens (S14). Health authorities tackle gene therapy
Project Manager Gene therapy remains an expensive medical path, however. S21 PERSPECTIVE
Rebecca Jones Moving it out of the laboratory and into the clinic will require Access and affordability for all
Creative Director innovative pricing schemes (S21) and regulatory policies Michael Sherman on value-based deals
Wojtek Urbanek
(S18). Along the way, clinicians, patients and policymakers
Publisher
Richard Hughes will grapple with tricky ethical questions (S7).
Editorial Director We are pleased to acknowledge the financial support of
Stephen Pincock Pfizer Inc. in producing this Outlook. As always, Nature has
Magazine Editor sole responsibility for all editorial content.
Helen Pearson
Editor-in-Chief Herb Brody
Magdalena Skipper Chief supplements editor
Nature Outlooks are sponsored supplements that aim to stimulate available for 6 months.
interest and debate around a subject of interest to the sponsor, SUBSCRIPTIONS AND CUSTOMER SERVICES
while satisfying the editorial values of Nature and our readers’ Site licences (www.nature.com/libraries/site_licences): Americas,
expectations. The boundaries of sponsor involvement are clearly institutions@natureny.com; Asia-Pacific, http://nature.asia/
delineated in the Nature Outlook Editorial guidelines available at
go.nature.com/e4dwzw
jp-contact; Australia/New Zealand, nature@macmillan.com.au; This special report first appeared in Nature
Europe/ROW, institutions@nature.com; India, npgindia@nature.
CITING THE OUTLOOK com. Personal subscriptions: UK/Europe/ROW, subscriptions@ [13 December 2018 | Vol. 564 | Issue No. 7735].
Cite as a supplement to Nature, for example, Nature Vol. XXX, nature.com; USA/Canada/Latin America, subscriptions@
No. XXXX Suppl., Sxx–Sxx (2018). us.nature.com; Japan, http://nature.asia/jp-contact; China, http://
Internal references may vary from
VISIT THE OUTLOOK ONLINE nature.asia/china-subscribe; Korea, www.natureasia.com/ko-kr/ original version.
The Nature Outlook Gene therapy supplement can be found at subscribe.
www.nature.com/collections/gene-therapy-outlook CUSTOMER SERVICES
It features all newly commissioned content as well as a selection Feedback@nature.com
of relevant previously published material that is made freely Copyright © 2018 Springer Nature Ltd. All rights reserved.
S3
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
JOHN FEDELE/GETTY
NEONATOLOGY
BY SARAH DEWEERDT born normally, and lived for at least 18 weeks evidence yet that the approach could be fea-
with little evidence of brain pathology. “You’re sible in humans. “The combination of those
I
n July, an international team of researchers talking about prolonging life significantly,” two aspects of the study made it very, very
reported that they had used gene therapy says Jerry Chan, a fetal-medicine specialist at exciting,” says Bill Peranteau, a fetal surgeon
to correct a fatal brain disorder in mice — Duke-NUS Medical School in Singapore and at the Children’s Hospital of Philadelphia in
before the mice were even born1. an author of the study. Pennsylvania.
The mice had a defect in a gene known as The researchers also administered the The technical challenges, safety concerns
GBA, which encodes an enzyme responsible gene therapy to healthy macaque fetuses, and and ethical issues of prenatal gene therapy are
for breaking down a fatty molecule called showed that it could transform brain tissue substantial. But this approach is more than just
glucocerebroside. Without the enzyme, glu- without serious side effects in an animal model hotshot medicine. It could be the best way to
cocerebroside builds up in the brain, causing that more closely approximates the body size treat a select group of devastating genetic dis-
irreversible brain damage. The mice typically and pregnancy physiology of humans. eases — and perhaps the only way to achieve
die within about 14 days of birth. “What we were trying to do is show the best a lasting cure.
The mice model a condition in humans possible experiments that would justify, if
called acute neuronopathic Gaucher’s disease. there ever was, a path to human clinical trans- EARLY ADVANTAGES
Children born with this genetic mutation lation,” says study leader Simon Waddington, a Acute neuronopathic Gaucher’s disease is one
rarely live past the age of two. gene-therapy researcher at University College of the best candidates for treatment with pre-
In the study, researchers injected a virus London. natal gene therapy. That’s because the build-up
bearing an intact copy of the GBA gene Other researchers in the small field of of glucocerebroside begins in the fetus. In the
into the brains of fetal mice about mid-way prenatal gene therapy see the research as a absence of any intervention, irreversible brain
through gestation. The treated mice were leap forward, and say it provides the strongest damage can occur even before birth. “The
S4
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
main advantage is preventing the damage from therapy is fairly straightforward. It involves Often, scientists have looked to the prenatal
occurring in the first place,” Waddington says. injecting the treatment into an umbilical window not just for the opportunity to treat
With other genetic diseases, the effects blood vessel, the amniotic fluid or occasionally diseases that begin before birth, but as a way
might not begin until sometime in infancy or directly into fetal tissue — often with the guid- around some of the difficulties of postnatal
early childhood. But even then, prenatal gene ance of an ultrasound probe. The techniques gene therapy. Charles Coutelle at Imperial
therapy might be more effective or efficient are similar to well-established methods used College London, says that what prompted him
than waiting until after birth. “You are trying in amniocentesis, chorionic-villus sampling or to enter the field in the mid-1990s was, “to be
to take advantage of the normal developmental umbilical-vein blood transfusion. quite frank, frustration with the efficiency of
properties of the fetus to increase the efficiency “The procedures themselves are relatively gene therapy at the time”.
and the likelihood of success of the treatment,” safe,” says David. Still, they do come with a Coutelle had been involved in one of the first
says Peranteau, who is working on animal small risk of infection, preterm labour and human trials of gene therapy for cystic fibro-
studies of prenatal gene therapy for metabolic loss of the pregnancy. All in all, she says, “it’s sis, a genetic disorder that affects the lung and
diseases affecting the liver. going to be a lot safer, probably, to treat it after other organ systems. It was difficult to deliver
Before birth, the blood–brain barrier that the baby is born when you’ve got the baby and gene therapy to the lungs of people with cystic
prevents many molecules from crossing from you’re not risking the mother”. fibrosis because even in young children, the
the bloodstream into brain tissue is imma- Then there are the usual risks involved in airways were full of viscous mucus and scar
ture, a situation that eases delivery of genes to gene therapy, such as the potential for the tissue; immune-system
the central nervous system. In a 2011 paper2, vector to provoke an immune reaction in “You are dysfunction also pre-
Waddington and his colleagues showed that the patient, or incorporate into the genome trying to take sented a hurdle. Coutelle
a gene-therapy vector called AAV2/9 reaches in a location where it could trigger cancer. advantage of thought it might be
nerve cells in the brain much more reliably in Some of these risks are magnified in the pre- the normal easier to correct cystic
fetal mice than in those already born. natal setting. For example, if the gene therapy developmental fibrosis in utero, when
Another advantage of prenatal intervention gets into the mother’s bloodstream, it could properties of amniotic fluid moves
is that the immune system is still immature. cause a dangerous immune reaction in her the fetus.” freely in and out of the
Therefore, the packaging used to deliver gene body or even be incorporated into her cells. lungs.
therapy — whether a virus or another type of In the fetus, especially if given early in Coutelle and his team spent several years
vector — might be less likely to cause an adverse development, the gene therapy could alter perfecting fetal transfer techniques in mouse
reaction. Also, the body develops immune germ cells that will eventually develop into models, as well as working out which vectors
tolerance to the vector, so if a gene therapy eggs and sperm, causing changes that could would be best to use prenatally against cystic
‘booster shot’ needs to be administered later in be passed down to eventual offspring — a pos- fibrosis or other serious diseases. The first big
life, it is more likely to succeed. The immune sibility that many scientists consider ethically success — and an achievement that remains
system will also accept the normal protein problematic. The therapy might also disrupt significant today — came in 2004. That year,
encoded by the gene therapy, rather than normal body-system development by trigger- a group including Coutelle and Waddington
destroying it — as has sometimes been seen ing the expression of genes in an inappropriate corrected the bleeding disorder haemophilia B
with postnatal gene therapy and protein- place or at an inappropriate time. That could in prenatal mice by injecting them with a virus
replacement therapies. potentially cause lasting effects, such as organ bearing an intact copy of factor IX, a protein
In addition, rapid fetal growth and malformation. involved in blood clotting4.
development means more bang for the gene- Parents facing an in utero diagnosis of a But the team soon had to switch gears. One
therapy buck. At any given time, a large serious genetic condition must often decide vector used in the haemophilia work yielded
proportion of cells in the fetus is actively whether to raise a child with a lifelong disabil- only a temporary cure; another produced
dividing. That yields a greater likelihood of ity or terminate the pregnancy. The appeal of more lasting results but led to an increased
the vector integrating into the genome. The prenatal gene therapy is that it offers a poten- risk of liver tumours. More importantly, the
population of corrected cells will continue to tial third path. But these treatments also raise development of postnatal gene therapy for
expand throughout gestation. Furthermore, the stakes: what if the gene therapy doesn’t haemophilia had taken a sudden leap forward.
to effect a cure, it is important to get replace- work, leaving parents with a seriously ill child “Once you have an established postnatal gene
ment genes into stem cells or progenitor they weren’t prepared for and would not have therapy there’s no point in doing it prenatally.
cells — and these long-lived cells are more chosen to raise? Similarly, a gene therapy that Or you have to have good reasons for doing it,”
abundant and more accessible before birth. is only partially effective could turn a dis- Coutelle says.
Finally, a 20-week fetus weighs roughly ease that previously would have been fatal in
300 grams, whereas a newborn tips the scales infancy into one that results in long-term dis- A SURFEIT OF TARGETS
at around 3.5 kilograms. That small size trans- ability — so it could actually increase suffering Waddington decided to look for a more
lates directly into a higher therapeutic effect for the patient and family. challenging target disease that causes more
from a given dose of treatment. That’s a big As a result of such concerns, researchers are severe effects earlier on, which led him to
advantage because gene-therapy products can cautious about the prospect of attempting pre- Gaucher’s disease. But that is just one of a fairly
be expensive and laborious to produce. natal gene therapy in humans. “If there is an broad array of metabolic disorders, including
adequate treatment for something after birth, Tay–Sachs disease, Niemann–Pick disease and
A RISKY BUSINESS that is the way to go,” Peranteau says. mucopolysaccharidosis, that cause in utero
But the fetal time period also poses unique damage and could therefore be good targets
challenges. Any prenatal intervention is com- ORIGIN STORY for prenatal gene therapy.
plex because it affects two people — the mother Even so, scientists have been thinking about Other researchers argue that haemophilia
and the fetus. “You’ve always got to take both prenatal gene therapy for nearly as long as they remains a good prenatal target. Researchers
into consideration, and you’ve also got to think have been working on postnatal gene therapy. led by Graça Almeida-Porada and Christopher
about the future children of the mother her- The first proof-of-concept studies3 in animal Porada at Wake Forest University in Winston-
self,” says Anna David, a fetal-medicine special- models, showing that a gene could be intro- Salem, North Carolina, are working with a
ist and gene-therapy researcher at University duced into an organism before birth, were sheep model of haemophilia A. This form of
College London. published in 1995 — just a couple of years after haemophilia accounts for about 80% of hae-
Generally, the delivery of prenatal gene the first human gene-therapy trial. mophilia cases in humans, but has proven
S5
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
much more difficult to address with postnatal going to reach clinical practice much faster,” Clinicians would need to be able not only
gene therapy than has haemophilia B. says Chan. The safety of stem-cell or bone- to detect a disease before birth, but also to
One major issue is that the protein involved marrow transplantation is better established confidently predict that its severity would be
in haemophilia A — factor VIII — is highly than that of gene therapy, he says. sufficient to warrant gene therapy. These are
immunogenic. Many people with a severe complex questions that aren’t fully resolved
form of haemophilia A develop antibodies A BOON FOR RESEARCH for all the prenatal target disorders. However,
against factor VIII, which makes replacement But even if prenatal gene therapy doesn’t reach if there is no prenatal treatment for a disease,
therapy more costly and complicated, says the clinic, it could still be useful as a research there might be little point in identifying it
Almeida-Porada. “The goal of going prior to tool. That’s already the case with cystic fibro- in utero.
birth is that you would induce tolerance to the sis, says Marianne Carlon, a gene-therapy Waddington’s attitude is simply to bypass
protein — these patients would never develop researcher at the Catholic University of Leuven this catch-22 situation. “We’ll develop the
an immune response,” she explains. The team in Belgium. cures, and then that justifies doing the diag-
aims to cure haemophilia A in fetal sheep by noses,” he says.
collecting stem cells from the amniotic fluid, On the flip side, the first prenatal gene
S6
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
PERSPECTIVE
A genetically augmented future
Gene therapy could one day be used for bodily enhancement, creating
an ethical minefield for physicians, says Ellen Wright Clayton.
T
he year is 2030. Gene therapy to insert the DNA sequence for The request might reflect issues with self-image. The desire to be
dystrophin has been approved by regulators and is commonly stronger could reveal a psychological problem that needs to be resolved.
used in children with Duchenne muscular dystrophy (DMD), Or a physician could conclude that Alex is suffering, thereby making
a disorder linked to the X chromosome. Evidence shows that the inter- the case for gene therapy more compelling. For example, medical and
vention increases muscle mass in anyone who receives it. The treatment surgical interventions are sometimes prescribed to prevent or relieve
is widely available, but very expensive. psychological distress in children or young people who are abnormally
Alex, a slender adolescent, walks into a physician’s office, short3 or who have potentially stigmatizing physical features4. It is
accompanied by well-to-do parents. Alex does not have DMD, but important to ensure that Alex understands and agrees to the therapy,
wants to be stronger. Exercise is not providing enough benefits, and but in the end, it can be hard to ascertain the source of a person’s desire
anabolic steroids have too many side effects. Alex is adamant about for a given treatment — especially if the person is an adolescent.
wanting dystrophin gene therapy and accurately cites its risks and Are Alex’s parents wrong to support their child’s desire? Perhaps they
benefits. Alex’s parents are willing to pay for the treatment. are putting undue pressure on Alex. Perhaps they want to alleviate Alex’s
The cure for DMD described previously represents a cherished goal distress. Perhaps they are just indulgent. Society’s default position is that
for gene therapy, and there is a lot of public support for fixing such herit- parents should have the last say in such matters because they are assumed
able disorders in this way1. Yet Alex’s request raises a host of questions. to care more for their children than does anyone else. Parents have a
We do not know why Alex wants to be stronger. responsibility for shaping their children’s future,
Alex could have a milder form of muscular creating opportunities and drilling into them all
dystrophy or, if female, could be a carrier who sorts of values. Parents are largely free to pursue
experiences milder symptoms of DMD2. Alex
might have some other cause of muscle weak-
CONCERNS their vision for their children’s lives, unless those
actions are illegal or constitute abuse or neglect.
ness — or might want to be stronger for the sake of ABOUT EQUITY So what is the physician to do? Assuming that
appearance, or to be more competitive in athletics.
As is the case for many medical interventions, the
SHOULD LEAD gene therapy for enhancement has not been out-
lawed, he or she can and should turn to medical
potential uses of this therapy go beyond the spe- SOCIETY TO DEVELOP ethics and the goals of medicine5 for guidance.
cific disease for which it was developed. Possible
applications range from treating milder disease to GUIDELINES Respect for persons — a fundamental principle
of medical ethics — would direct the physician
improving human characteristics — a continuum
that could lack clear boundaries. FOR GENE THERAPY to attempt to discover more about what is driv-
ing the patient and their parents’ wishes, and to
Let’s assume that Alex does not have a TO AVOID A ensure that they understand what is at stake and
diagnosed physical problem and wants the ther-
apy simply to become stronger. The main debate NIGHTMARE that their expectations are realistic6. If the deci-
sion to proceed was made to relieve suffering,
FUTURE.
about using medical interventions for such bodily and with the adolescent’s informed assent and the
enhancements focuses on the extent to which they parents’ permission, pursuing the goals of medi-
give individuals an advantage over other people. cine would lead the physician to use the therapy
A 2017 report by the US National Academies on to confer only traits within the normal range of
gene editing in humans captures the debate well1. human characteristics.
The authors summarize surveys that show that most people disapprove Ultimately, the ethics of enhancement are intertwined with views of
of using gene therapy to improve a person’s physical and intellectual fairness. Concerns about equity should lead society to develop guide-
characteristics. The public tends to honour narratives of success based lines for gene therapy to avoid a nightmare future in which a group of
on personal diligence, or even accident of birth, over traits that can be privileged people becomes stronger, smarter and more beautiful than
purchased. This preference touches on a larger issue: the extent to which the rest. But because drawing lines between treatment and enhance-
uses of gene therapy would exacerbate social inequality. If there is a ment is difficult, the more likely and more unsettling scenario is that
widespread perception that this would be the result, society might try physicians will be left to rely on their own ethical commitments to
to limit its use to the few people who genuinely need it to treat their decide when to use gene therapy. ■
disease. Or there might be an effort to make such therapies available to
all who want them. Ellen Wright Clayton studies medical ethics and health policy at
Back to Alex in the world of 2030. Assuming that the US Food and Vanderbilt University Medical Center in Nashville, Tennessee.
Drug Administration’s regulations are still the same, physicians would e-mail: ellen.clayton@vanderbilt.edu
be free to use the approved DMD intervention for any purpose. After 1. US National Academies of Sciences, Engineering and Medicine. Human
all, many medicines are legally prescribed for reasons that have noth- Genome Editing: Science, Ethics, and Governance (National Academies, 2017).
ing to do with their original indication. So what should happen? How 2. Papa, R. et al. Pediatr. Neurol. 55, 58–63 (2016).
hard should a physician try to understand the source of Alex’s desire 3. Grimberg, A. et al. Horm. Res. Paediatr. 86, 361–397 (2016).
4. Rohrich, R. J. & Cho, M.-J. Plast. Reconstr. Surg. 142, 293e–302e (2018).
to be stronger? 5. Allert, G. et al. Hastings Cent. Rep. 26, S1–S27 (1996).
Alex’s wish might be a product of the social and cultural environment. 6. Grady, C. N. Engl. J. Med. 372, 2172 (2015).
S7
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
Elizabeth Nicholson and Dimitri Kullmann at University College London. RESTORING BALANCE
The brains of people with epilepsy contain
N E UROLOGY increased amounts of neuropeptide Y (NPY), a
chemical that certain neurons release when they
T
he seizures of around one-third of epileptic seizures. The most advanced projects showed that overexpressing the neuropeptide
people with epilepsy are resistant to avail- are now being readied for clinical trials. galanin likewise suppressed seizures.
able medicines — a statistic that haunts Kokaia, who was already working on NPY
neurology. It has been this way for decades. The EXCITATION AND INHIBITION and epilepsy at the time, became interested
medicines have got better by becoming safer Epilepsy comes in many forms. It is defined in the therapeutic potential of this approach
and causing fewer side effects. But still there by the repeated occurrence of seizures — but and started experimenting with introduc-
are people for whom the drugs simply don’t these seizures can vary in their nature, inten- ing genes for neuropeptides, their receptors
work — and for them, epilepsy can be ruinous. sity and frequency. And the disorder can arise or both. He found that overexpressing NPY
“There’s stigma; they can’t drive; they have from numerous causes, progress in different alone decreased seizure frequency, but simul-
difficulty holding down jobs; they have diffi- ways and affect distinct parts of the brain. taneously overexpressing it with the inhibi-
culty maintaining relationships,” says Dimitri Crucially, epilepsy can either be focal, with tory Y2 receptor dramatically heightened the
Kullmann, a neurologist and neuroscientist at seizures beginning in a specific brain region, anti-seizure effect2. “What we are trying to do
University College London (UCL). or generalized, with seizures developing across is boost the natural response of the brain by
Currently, the main hope for people with wide spans of the brain. Focal epilepsy is more gene therapy,” says Kokaia.
severe drug-resistant epilepsy is surgery. Some- common, and it can be further subcategorized In 2015, Kokaia co-founded CombiGene in
one whose seizures arise from a well-defined according to whether the seizures remain focal Lund, Sweden, to commercially develop this
region of the brain might be offered an opera- or spread to become generalized. There is also technique. In the past two years, CombiGene
tion to remove that region. This is a drastic pro- variation in the size of the seizure-generating has confirmed the anti-seizure effects of the
cedure, but not especially rare; it is carried out focus and whether it is discrete, and therefore NPY–Y2 combination therapy, now called
about 500 times every year in the United States. potentially removable, or enmeshed with vital CG01, in further rodent models of epilepsy.
Kullmann is hoping that gene therapy can brain tissue, and thus inoperable. And the company has successfully introduced
make such surgery unnecessary. His group and Brains essentially work by relaying electri- the NPY and Y2 genes into brain tissue that was
others are investigating the potential benefits cal signals from neuron to neuron through surgically removed from people with epilepsy.
of introducing different genes into the brains of the release of chemical neurotransmitters. Experiments using such tissue also ended
S8
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
S9
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
STEVE BABULJAK/UCSF
costs that insurers might not be able to cover
the treatment, even if it saves them money
in the long term.
The only current cure for sickle-cell disease
is a bone-marrow transplant from a matched
healthy donor. The stem cells that serve as
blood-cell factories — haematopoetic stem cells
— are removed from the donor’s bone marrow
or blood, then infused into the recipient. If the
transplant works, the donor’s stem cells churn
out non-sickle-shaped red blood cells, curing
the disease. Donors can be a sibling or some-
one unrelated with the same bone-marrow type,
but less than one-third of people with sickle-cell
disease can find a matched donor.
Gene therapy could provide a cure for many
more people because it doesn’t rely on a donor:
instead, stem cells are harvested from the
patient’s own bone marrow. As a further benefit,
gene therapy avoids conflict between the donor’s
and recipient’s cells. After a bone-marrow trans-
plant, doctors have to suppress the recipient’s
immune system to prevent it from attacking the
transplant, which leaves the patient vulnerable
to infection. Even then, the donor cells might
attack the recipient’s cells, resulting in graft-
versus-host disease — the leading cause of death
after a bone-marrow transplant. Gene therapy
Six-year-old twins Tylee and Taleeke both have sickle-cell disease. eliminates this concern.
E
lliott Vichinsky estimates that at least Gene therapy might offer a cure for sickle- the trial, and they receive blood transfusions
30% of his adult patients with sickle- cell disease, and clinical trials are already every 3–4 weeks to reduce the percentage of
cell disease die from preventable under way. “In the long run I think it will be sickle cells in their blood, says Walters. “We
causes. Red blood cells are supposed to be able to cure the disease,” says Vichinsky, a hae- don’t want patients having complications in the
shaped like concave discs, but in people with matologist and oncologist at the University of middle of the trial or leading up to it.”
sickle-cell disease, a mutation in a single gene California, San Francisco (UCSF) Benioff It takes about a month for the new gene to
collapses them into a crescent shape. The Children’s Hospital in Oakland. The approach be inserted into the patients’ stem cells. After
pointy sickles catch on each other and clog is promising because just a single gene needs being collected up, the cells are shipped over-
blood vessels. They cut off oxygen to limbs. correcting: the one for the β-globin subunit night by plane to a central manufacturing
They cause kidney failure, hypertension, lung of haemoglobin, the body’s oxygen ferry. location, where they spend several days just
problems and strokes — along with bouts of But Vichinsky is concerned that the same multiplying. Then scientists put the β-globin
excruciating pain. problems that make current care ineffective gene into the stem cells using LentiGlobin
Thes e are common and treatable will also plague this gene-therapy treatment. BB305, a vector made from a virus. After qual-
complications, so why the high death rate? As his patients attest, sickle-cell care is often ity-control testing, the improved stem cells are
Vichinsky attributes it to a lack of infrastruc- inadequate for reasons that have little to do frozen and shipped back to UCSF Benioff.
ture, such as care centres, to properly monitor with scientific advancement and lots to do with In the meantime, the patients receive four
adults with sickle-cell disease. This is partly economics and racism. days of intensive chemotherapy to wipe out any
because the disease mainly affects low-income For people with sickle-cell disease in the remaining stem cells with the old, problematic
minorities and people in developing countries. United States, paying for the treatment could version of the gene. The improved stem cells
S10
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
A COSTLY ENDEAVOUR
The clinical trials will demonstrate whether
gene therapy is effective at curing sickle-cell
disease. But even if it is, the cost of treatment
is likely to be very high. For example, voreti-
gene neparvovec (Luxturna), a gene therapy
for degenerative blindness, costs US$425,000
per eye. “We’re looking upwards of $500,000 to
$700,000” for sickle-cell gene therapy, spread
over multiple years, says Stephanie Farnia,
director of health policy and strategic relations
at the American Society for Blood and Marrow
Transplantation in Chicago, Illinois. And this is
a disease for which more than 50% of patients
in the United States rely on government health
insurance such as Medicare and Medicaid.
In the long term, an expensive cure for
sickle-cell disease would probably be cheaper
than — and much more preferable to — dealing Normal red blood cells (red) compared with the elongated blood cells in sickle-cell disease (pink).
with 30–40 years of the disease’s chronic, long-
term effects. But even if the pharmaceutical one-third who have a suitable bone-marrow just because there’s no basic care available,” he
company spreads the cost to insurers over donor, it doesn’t open it up to everyone. “It’s says. The US Centers for Disease Control and
5–7 years, Farnia says, insurers, particularly still an intensive procedure,” says Walters, Prevention list 175 providers of paediatric
government-funded ones, will probably not particularly the high dose of chemotherapy care for sickle-cell disease in the United States,
have sufficient capital to pay for everyone who that people receive before the stem cells are but only 44 providers of adult care. Vichinsky
wants the treatment. “The really tough part is returned to their bodies. “Not everybody is started his own adult programme because he
these budgets do not have a lot of room in them well enough to go through it.” had nowhere else to transfer his young patients
for additional costs,” Farnia says. It’s like trying Recruiting for clinical trials might also be a when they became adults. “It has to do I think
to pay for an entire 30-year mortgage in just problem. Current trials involve small numbers with money and ethnicity,” he says.
five years, she says. “You’re going to save a lot of people with sickle-cell Basic care for sickle-cell disease should be
more money down the road, but can you come disease, but if the treat- “Sickle-cell modelled on current programmes for cystic
up with the money to do that?” ments work, future trials fibrosis or childhood cancer, says Vichinsky.
disease
For a possible preview, Farnia suggests will require many more He advocates that sickle-cell-disease medical
looking to chimeric antigen receptor T-cell participants. In the United
represents centres should include multidisciplinary teams
(CAR-T) therapy — a type of immunotherapy States, sickle-cell disease
the best and to monitor people for the degenerative effects
that has shown promising results in treating is more common among worst of of sickle cells across many different organ sys-
certain types of cancer. US medical centres black and Hispanic popu- health care tems, such as the lungs, heart, kidneys, spleen
and hospitals are paying for CAR-T therapy lations, and there is an ugly in the United and brain. That way, doctors could detect early
up front to treat their patients, before know- history of non-consensual States.” warning signs of problems such as renal failure
ing whether insurers will reimburse them medical research on black and hypertension.
for it. “And they have to hope they can figure people, causing some to be wary of participat- He is optimistic, however, that sickle-cell gene
out with payers that they get reimbursed for ing in clinical trials. And racial bias also gets in therapy might act “as a kind of door opener to
enough of that,” Farnia says. the way of treating the disease. “The hallmark the field of gene therapy”. There are a handful of
of sickle-cell disease is pain, and it’s excruciat- gene-therapy drugs on the market, but sickle-
CHALLENGES AHEAD ing pain. It’s like putting a tourniquet on and cell disease’s role as an early gene-therapy target,
There are other concerns with gene therapy depriving a limb of oxygen,” says Walters. And and the promise of that therapy, might attract
as well. For one, more long-term monitoring unfortunately, doctors have been shown by interest in how best to care for people with this
is needed. The added gene slips in at random multiple studies to be less likely to believe black disease, and propel standards of care forward.
places in each stem cell’s genome, so it has people’s claims to be in pain than white people’s “Sickle-cell disease represents the best and
thousands of opportunities to land in the (see, for example, K. M. Hoffman et al. Proc. worst of health care in the United States,”
middle of another important gene. It could Natl Acad. Sci. USA 113, 4296–4301; 2016). Vichinsky says. Technologically advanced
theoretically wind up in a gene that suppresses Sickle-cell disease is a chronic condition. gene therapy is a hot research area, but not
cancer. No one has yet observed a leukaemia Management of chronic diseases isn’t typically yet proven to work. Mundane chronic illness
caused by delivering treatments with the fam- groundbreaking, and even among chronic dis- care is neglected, but it would save lives. “Most
ily of viral vectors that LentiGlobin BB305 eases, sickle cell is typically neglected. “It’s not adults don’t have access to multidisciplinary
belongs to, Walters says, but a stem cell is received the attention or the national funding services,” says Vichinsky. “I believe to some
long-lived. “If you treat a child, it’s going to be that it maybe should have received, because it’s extent that gene therapy will actually stimulate
a source of blood for the next 50–60 years.” No not as politically connected,” says Walters. the medical and scientific community to bring
patients have been monitored for anywhere Vichinsky argues that gene therapy should that to sickle cell.” ■
near that long after gene therapy. be part of a multidisciplinary programme that
Although gene therapy opens up bone- includes basic care, not a substitute for basic Anna Nowogrodzki is a science writer based
marrow transplants to more people than the care. “We shouldn’t push them into gene therapy in Boston, Massachusetts.
S11
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
DE RMATOLOGY
Under
the skin
The largest organ in the
body is a prime target for
gene therapy.
B Y K AT A R N E Y
I
t’s not often that a figure in a scientific
paper can make you wince with pain.
But it’s impossible to look at figure 1a in
Michele De Luca’s 2017 Nature paper and
not feel a sympathetic twinge at the sight of a
young boy, Hassan, covered from head to toe
with red-raw wounds1.
The son of Syrian refugees who fled to
Germany, Hassan was born with junctional clinical experience, so it was obvious to try and version of LAMB3. The next challenge was
CMR UNIMORE
epidermolysis bullosa (JEB) — a condition genetically modify these cells for treating rare growing enough 12-centimetre-square sheets
caused by a genetic fault in one of three genes skin diseases like JEB,” De Luca says. of modified cells for Ruhr University plastic
(LAMA3, LAMB3 and LAMC2) encoding sub- The idea of growing genetically modified skin surgeon Tobias Hirsch to wrap around the
units of the laminin-332 protein, which binds for therapeutic use was first proposed in 1994 by child’s fragile body.
the surface of the skin to the underlying layers. dermatologist Gerald Krueger at the University After two major operations to replace the
Affected children rapidly develop large, pain- of Utah in Salt Lake City2, and De Luca and skin on Hassan’s limbs and torso, followed by
ful blisters over their skin and internal mucous his team reported the results3 from an initial some smaller procedures, around 80% of the
membranes, which can easily become infected. small clinical trial of genetically modified skin entire epidermis had been replaced, making
By 2015, when Hassan was seven, his skin grafting back in 2006. it the largest genetically modified graft per-
was almost entirely destroyed and he was The recipient was a 36-year-old man with formed to date. By the time the results were
suffering from severe bacterial infections. JEB caused by a LAMB3 mutation. He was published in 2017, Hassan was like a different
Doctors at Ruhr University in Bochum, treated with nine small patches of skin that child, his raw blisters replaced with smooth,
Germany, could offer only palliative care were grown from his own epidermal cells perfectly functional skin.
to relieve his suffering. But Hassan’s father and modified with a viral vector expressing
enquired about experimental treatments, and the missing gene. The grafts remained stable
XIAOYANG WU/CYNTHIA LI
the doctors got in touch with De Luca at the and healthy for more than a year, proving that
University of Modena and Reggio Emilia, Italy, the technique had the potential to provide
who was working on a radical skin therapy. long-term correction of the condition.
De Luca’s research builds on the life-saving
work of cell biologist Howard Green at the UNSCHEDULED INTERRUPTION
Massachusetts Institute of Technology in Despite this early success, De Luca’s clinical
Cambridge. Green was the first to discover that work ground to a halt for nearly a decade owing
sheets of skin cells could be grown in the labo- to European Union legislation governing cell
ratory, creating personalized skin grafts that and gene therapies. “The regulations regarded
avoid the problems of immune rejection. De our grafts as medical products, so they had to
Luca worked with Green at Harvard Medical go through the same regulatory process,” he
School in Boston, Massachusetts, in the sighs. “We had to stop all our activities, build up
1980s, and he later decided to develop Green’s a compliant manufacturing facility and register
approach for treating genetic skin conditions the therapy — it was only in 2015 that we were
by genetically modifying the skin cells to fix finally able to start our trials again.”
the disease-causing mutation. Luckily, this was just in time for Hassan.
“We’ve been using epidermal skin-cell De Luca’s team took a tiny unblistered skin
cultures for many years to treat hundreds sample from the child’s groin, then carefully
of patients, carrying out a lot of work on cultured the epidermal stem cells and modified
basic stem-cell biology as well as gaining them with a viral vector carrying a functional A skin graft with fluorescent staining.
S12
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
They then grew the cells into small skin grafts epidermolysis bullosa, which can be caused by a
and transplanted them onto the backs of mice. fault in any one of at least 18 different genes and
The researchers found that the engineered affects around 1 in every 20,000 children born
skin grafts could successfully secrete GLP1 in the United States. And it’s by focusing on the
into the animals’ blood in response to the drug, youngest patients, who have the most to gain
slowing weight gain and preventing diabetes in from early intervention, that De Luca hopes to
mice kept on a high-fat diet. make the biggest difference.
Wu’s team has now used this technique to “If we treat these children as soon as we can,
create similar patches of CRISPR-modified we will prevent the formation of skin lesions
skin cells that produce a tweaked version of rather than having to cure them — and, obvi-
an enzyme called BChE, which breaks down ously, we need to grow less skin to cover them,”
cocaine5. Wu’s version metabolizes the drug he says. “If you asked me 30 years ago if it was
more than 4,000 times faster than the natu- realistic to replace
rally occurring form, rapidly clearing it from “After three the whole skin with
the body and quickly killing the ‘high’. years, his skin transgenic epidermis,
When tested in mice, the skin patch stopped is stable with I would have said no,
the animals from becoming addicted to cocaine no blistering, but we have done it.
and prevented them from overdosing, pointing and it should The final aim of my
towards a potentially promising treatment for last a lifetime.” career is to make this
people with drug addictions. Wu and his team gene therapy a real
are also working on skin patches that could treatment for children — not a clinical trial
serve as long-term living biosensors — for or a demonstration of what we might do, but
example, engineering cells that change colour something that is used to treat everyone who
or fluoresce in response to blood glucose levels. needs it.”
“Many researchers are focusing on gene Three years on from his record-breaking
A sheet of therapy for internal organs like the liver, but skin replacement, Hassan is living testament
genetically the skin is much easier — we can culture the to this possibility, regularly visiting the team
modified cells indefinitely and do the editing outside the in Modena for check-ups.
skin cells. body,” Wu explains. “We can also very care- “When he was in hospital he weighed just
fully choose the correct clones to grow up into 17 kilos and was dying, but now he is growing
patches, with no off-target effects or rogue up,” De Luca says proudly. “I last saw him two
As well as detailing Hassan’s progress, the genetic changes.” weeks ago and he is like a mascot for the insti-
paper1 reveals why the treatment was a success. But human trials are likely to be some years tute — there is a big celebration every time we
The skin is made up of many different types off. “Right now we are still at the proof-of- see him, and everyone who was involved in his
of cells, some that are short-lived and others concept stage,” Wu says. “Once the technology treatment wants to give him a hug.” ■
that are much more persistent. The research- is more established and we are confident in the
ers showed that long-term grafting was only procedure, we can think about moving into Kat Arney is a science writer and broadcaster
possible if the genetically modified cells were clinical trials to treat diseases.” living near London.
holoclones — a relatively rare type of immortal Although De Luca finds this idea intriguing,
cell that can self-renew indefinitely. By adjust- he is more focused on making genetically modi- 1. Hirsch, T. et al. Nature 551, 327–332 (2017).
2. Krueger, G. G. et al. J. Invest. Dermatol. 103,
ing the culture conditions, De Luca and his fied skin replacement a viable treatment for the 76S–84S (1994).
team were able to encourage the growth of thousands of children born every year with 3. Mavilio, F. et al. Nature Med. 12, 1397–1402 (2006).
holoclones, greatly increasing the chance that genetic skin disorders. He is currently running 4. Yue, J., Gou, X., Li, Y., Wicksteed, B. & Wu, X. Cell
Stem Cell 21, 256–263.e4 (2017).
the resulting grafts would work. two clinical trials for people with different forms 5. Li, Y. et al. Nature Biomed. Eng. https://doi.
“After three years, his skin is stable with no of JEB, but is keen to expand into other forms of org/10.1038/s41551-018-0293-z (2018).
blistering, and it should last a lifetime,” says
De Luca. “There are still some areas of blister-
RUHR-UNIVERSITY BOCHUM
S13
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
SAM FALCONER
and gene therapy, researchers are working to
bring treatments based on antibody gene trans-
fer into clinical trials, using infectious diseases
as a proving ground. The approach also holds
promise for tackling non-infectious conditions
such as cancer. “Wherever antibodies work, we
believe this technology can work in the same
way,” Padte says.
Antibody gene transfer has to overcome
the same hurdles relating to safety and deliv-
ery as does any other gene therapy, as well as
more-specific challenges such as getting cells
that don’t normally make antibodies to pro-
duce them in large quantities. “We know it
works [in mouse models]. You can do it for
another thousand disease indications and it
will work every time,” says Kevin Hollevoet, an
immunologist at the University of Leuven in
Belgium. The big question, he says, is whether
the approach can be applied to people.
PICK-YOUR-OWN ANTIBODIES
David Weiner, director of the Vaccine and
Immunotherapy Center at the Wistar Institute
in Philadelphia, Pennsylvania, has devoted
almost three decades to developing and refin-
ing DNA-vaccine technology. But about eight
years ago, Weiner realized that his work could
make an impact in a very different field. His
then-teenage daughter was diagnosed with
severe Crohn’s disease, and the only treatment
that worked for her was a monoclonal-
antibody drug that had to be injected several
times a month. Weiner took notice of the fast
IMMUNOLOGY growth of therapies based on monoclonal
antibodies, which include anti-inflammatory
O
utbreaks of infectious disease are teins. “There’s a short window of opportunity lab than to produce monoclonal antibodies.
becoming more common in many one has to halt an emerging infectious-disease The approach would also require fewer doses
parts of the world. Between 1980 breakout, and making antibodies takes time,” because lab-made DNA can last for weeks to
and 2010, the number of outbreaks reported says Neal Padte, chief operating officer at bio- months in the cell nucleus, while continuously
worldwide more than tripled every five years. technology company Renbio in New York City. instructing the cell to churn out antibodies.
Unexpected outbreaks caused by viruses such Padte belongs to a growing group of Since 2013, Inovio Pharmaceuticals in
as Ebola and Zika have led researchers to seek researchers who want to skip those steps by Plymouth Meeting, Pennsylvania, a company
faster and cheaper strategies for addressing simply giving the body the genetic information co-founded by Weiner, together with Weiner
pathogenic agents they know little about. These it needs to make the antibodies. This can be and his team at Wistar, has been develop-
strategies include using laboratory-made, achieved by delivering the DNA that encodes ing a number of DNA-encoded monoclonal
monoclonal antibodies that can immediately those antibodies to the cell nucleus — a process antibodies. It started by creating antibodies
bind to and neutralize specific viruses or bac- called antibody gene transfer. It’s similar to the to tackle viral infectious diseases such as
teria in a person who has been infected, but also idea behind DNA vaccines, which deliver DNA chikungunya and dengue fever and has now
protect, for a time, anyone who is likely to be that encodes vaccine components to cells. broadened its scope to develop such antibodies
exposed to a particular pathogenic species. The approaches differ in that DNA vaccines against antibiotic-resistant pneumonia and two
But monoclonal antibodies are expensive to are designed to trigger the immune system to proteins found at elevated levels in tumours of
produce, must be stored in the cold and often make its own antibodies, whereas antibody the prostate gland. They are now working on
require repeated administration by injection to gene transfer aims to introduce antibodies DNA-encoded monoclonal antibodies that
work. That’s not to mention the one to two years without inciting such an immune response. mimic antibodies against the Ebola virus from
S14
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
S15
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
THE RA PEUTICS
Special
delivery
By tweaking a virus’s shell,
Luk Vandenberghe thinks he
can transport genes into cells
much more efficiently and
cost-effectively.
B Y N E I L S AVA G E
L
uk Vandenberghe walks over to a shelf
in his office and picks up two fist-sized
objects. One is a more complicated
version of a Rubik’s Cube, with 20 individu-
ally coloured sides instead of the standard 6.
The other is an off-white glob of hard plastic
produced by a 3D printer. It’s studded with
bumps, dimples and repeating triads of vaguely
pyramid-like shapes, 20 in all.
Both are models of an adeno-associated virus
(AAV), a favourite vector among clinicians
for delivering genes to cells. Vandenberghe, a Luk Vandenberghe at Massachusetts
bioengineer who directs the Grousbeck Gene Eye and Ear in Boston holds a model
Therapy Center at Massachusetts Eye and Ear of an adeno-associated virus.
in Boston, is trying to work out what effect all
those tiny structures have on the behaviour
of the virus. His aim is to manipulate them to with which they penetrate tissue. The goal of Rubik’s Cube dilemma,” says Vandenberghe.
S16
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
of the other 19 amino acids in existence in turn the retina is a relatively small organ, and some
to see what changes. Then he moves on to the retinal diseases are so rare that it’s possible
next amino acid in the sequence and repeats that a single batch of the drug could treat the
the process. “With this approach, we know entire patient population in the United States,
what the effect is for every possible individual Vandenberghe says.
change,” he says. Using machine learning, he
predicts what will happen when single-amino- A WIDER CONCERN
acid changes are combined, then synthesizes The question of how to develop gene therapies
promising sequences and tests the AAVs in for rare diseases is of great concern to the US
mice or non-human primates. National Institutes of Health, says P. J. Brooks,
Kelsic and Church have founded a company, program director at the institute’s Office of
Dyno Therapeutics in Cambridge, Massachu- Rare Diseases Research in Bethesda, Maryland.
setts, to create vectors this way. Kelsic predicts “When people discuss business models around
that even for tissues such as the brain that can treatments for rare diseases, the basic assump-
already be targeted with AAVs, more-efficient tion is that there is a business model,” he says.
viruses will lead to improved therapies. The “But for some of these diseases where there’s a
greater achievement, however, will be the ability very small patient population, there may not be
to target organs that are currently hard to treat, one.” Brooks says Odylia is the first company
such as the lung and kidney. “As we improve he has heard of to try this non-profit approach.
delivery further it will enable new therapies The idea, Vandenberghe says, is to find
which just aren’t possible today,” he says. economies of scale by sharing resources and
scientific and commercial expertise across the
A DIFFERENT BUSINESS MODEL development of a range of drugs that are simi-
The companies that these researchers have lar to one another. If the same group of people
founded follow the standard for-profit model develops the drugs, designs the clinical trials
used by most biotechnology start-ups. But and produces the materials, there should be
Vandenberghe is taking a different approach less duplication of effort, he notes. Vanden-
with Odylia Therapeutics, a not-for-profit berghe also hopes that after creating two or
company he founded in February. Odylia aims three successful treatments, the company will
to develop therapies for what Vandenberghe be able to provide data to convince the FDA
calls “ultra-rare” genetic causes of blindness, that there are enough similarities between the
which he defines as those that affect 3,000 or drugs to enable them to use experience with
fewer people in the United States. The firm is one drug to help establish the safety and effi-
supported financially by Massachusetts Eye cacy of another. It is also possible that Odylia
and Ear and the Usher 2020 Foundation in will take development of a drug far enough
Atlanta, Georgia, a charity focused on curing in this model that a for-profit company will
the sight loss caused by Usher syndrome. One decide to buy it and complete the work, pro-
of the charity’s founders, Scott Dorfman, who viding funding for Odylia while reducing the
disorder called Usher syndrome that causes has two children with Usher syndrome, is chief pharmaceutical company’s costs and risks.
deafness and visual impairment3. Excited by the executive of Odylia. If Odylia does bring a drug to market, it will
potential of such a vector, Vandenberghe and So far there is only one available gene therapy probably be sold at cost, Vandenberghe says.
his colleagues founded a company, Akouos, in for blindness. In late 2017, the US Food and That could still be expensive, but possibly less
Boston to develop treatments for hearing loss. Drug Administration (FDA) approved voreti- so than if it had been developed the usual way.
In August, the start-up secured US$50 million gene neparvovec (Luxturna) for the treatment There is also a chance that if a drug candidate
in a first round of investment. of eye disease caused by a mutation in the RPE65 gets through phase I and II clinical trials, the
Vandenberghe’s team is also collaborating gene, which normally produces a protein in the FDA could allow it to be provided on a com-
with Selecta Biosciences in Watertown, thin layer of cells at passionate-use basis without a final clinical
Massachusetts, which wants to develop gene the back of the eye. “As we improve trial, or that most patients could be treated as
therapies using Anc80. Vivet Therapeutics in As a proof of concept, delivery further part of an open-ended trial.
Paris is licensing the vector for use in devel- the treatment shows it will enable If the model is successful, it could be
oping treatments for inherited liver disease. that gene therapy can new therapies extended to other rare, single-gene disorders
And Lonza in Basel, Switzerland, is licensing be used to cure eye which just aren’t and perhaps provide insights for developing
the technique for making the virus so it can disease. But muta- possible today.” gene therapies for more common condi-
manufacture the vector for drug-makers. Back tions in more than tions. “Maybe this is one of those areas where
in 2011, before the Anc80 work, Vandenberghe 200 genes have been linked to hereditary eye industry can acknowledge that this is indeed
also co-founded GenSight Biologics in Paris to diseases, and Vandenberghe says that there is non-competitive,” Vandenberghe says. Ideally,
develop treatments for rare inherited retinal little appetite in the pharmaceutical industry for he says, that would set up a happy scenario.
diseases; the company currently has two drugs developing individual therapies to correct many “We can all come together around some of
in clinical trials. of the other genes. these common goals, apply them to ultra-rare
Creating better vectors is the key to It can cost millions of dollars to develop a diseases, and then take those lessons to the
expanding gene therapy, says Eric Kelsic, a drug and take it through clinical trials, and if more commercial world afterwards.” ■
systems biologist in the laboratory of molec- a disease is rare, it may not make economic
ular engineer George Church at Harvard sense for companies to pursue a treatment for Neil Savage is a science and technology
University. Kelsic is taking a data-driven it. That is a particular issue in gene therapy, journalist in Lowell, Massachusetts.
approach to capsid engineering. He selects an in which people are often cured with a single
1. Gao, G. et al. J. Virol. 78, 6381–6388 (2004).
amino acid from the protein sequence of an dose rather than a life-long drug regimen. The 2. Zinn, E. et al. Cell Rep. 12, 1056–1068 (2015).
AAV and systematically switches it with each doses required for eye diseases are tiny because 3. Pan, B. et al. Nature Biotech. 35, 264–272 (2017).
S17
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
REGULATING
A REVOLUTION
Health authorities
wade into the flood
of gene therapies.
BY ERIC BENDER
SAM FALCONER
S18
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
F
or rare genetic diseases that trials have gathered plenty of evidence about could come out of the blue. But that doesn’t say
affect the young, such as a therapies such as Luxturna that are delivered that gene therapy shouldn’t be made available
neurodegenerative condition by adeno-associated viruses (AAV), especially to patients.”
called spinal muscular atrophy, for systemic administration or for commonly
gene therapies bring much- targeted tissues such as the eye. Such AAV BETTER BY DESIGN
needed hope — a chance for the therapies often create a short-term immune Given the novelty and the potential risks and
child to live a relatively normal response in the liver, but this problem can gen- rewards of gene therapies, their sponsors
life. But they also raise serious fears about their erally be treated by using steroids. “For other tend to start working with regulatory agen-
efficacy and the potential risks that accompany target tissues, or for doses that are higher than cies early in development — often, very early.
irreversible one-off treatments. people have used to date, you may need addi- “Ideally, you talk with the agencies when you
The responsibility for balancing these hopes tional information,” High says. “There actu- are designing your preclinical development,”
and fears lies with the European Medicines ally are a wealth of approaches to overcome says Anne-Virginie Eggimann, vice-president
Agency (EMA) and the US Food and Drug immune response, and it’s a matter of doing the for regulation at biotech company Bluebird Bio
Administration (FDA). Their credentials as clinical investigations and finding answers.” in Cambridge, Massachusetts. “You can have a
gatekeepers to the therapies will soon be tested Barry Byrne, director of the Powell Gene general discussion with them on designing that
by a flood of clinical trials. This year the FDA Therapy Center at the University of Florida in programme, as well as how you see your first-
expects to receive about 250 applications to Gainesville, says it is far too soon to declare in-human clinical trial.” In October, Bluebird
start clinical trials for novel cell and gene thera- today’s gene therapies safe. “There’s very lim- Bio submitted a marketing application to the
pies, says FDA commissioner Scott Gottlieb. ited experience,” he cautions, “and there’s much EMA for its LentiGlobin gene therapy, which
Faced with rapid advances in biological more work to be done to understand how these is designed to treat a rare blood disease called
understanding and therapeutic delivery might be used in a variety of conditions.” transfusion-dependent β-thalassaemia.
technologies, the two regulatory agencies are There are many unanswered questions, such Like LentiGlobin, about 70% of the
establishing new guidelines for clinical trials as what happens if a patient who receives a investigational new drug (IND) applications
and are preparing to make tough decisions gene therapy delivered by AAV has previously for gene therapy submitted to the FDA are for
about which drugs to approve for marketing. been exposed to some form of the virus, or if rare diseases. Most of these conditions first
But drawing on their experience with hundreds proteins created by gene therapies provoke appear in childhood, and most of those have
of earlier studies, the agencies are confident that a reaction because the immune system has devastating results. But running a normal
they can assess gene therapies as effectively as not been trained to recognize them as ‘self ’, clinical trial, which includes large numbers of
they do any other novel therapeutics. Byrne adds. But he believes that strategies are subjects and a control arm, is often impossible.
emerging to avoid or control such immune “We know that in these situations you have
STANDARDIZING SAFETY problems. to exercise some flexibility, and that is exactly
Gene therapy has long been haunted by a very what we usually discuss with the companies
small number of deaths, originally in a 1999 when they come early,” says Eichler. “We nego-
US clinical trial and then in a European study
a few years later. However, a series of successful “YOU CANNOT tiate and see how can we get the best that is
doable in the circumstances.”
clinical trials over the past decade has created
sufficient confidence to move forward with
these treatments.
HAVE TWO Given the devastating nature of many rare
inherited diseases that strike children, parents
often press for accelerated clinical tests. But
One milestone, in December 2017, was the
first FDA approval of an in vivo gene-therapy STANDARDS developers emphasize that lowering safety
standards is not an option. “I really understand
product, for Luxturna from Spark Therapeu-
tics, based in Philadelphia, Pennsylvania.
Luxturna treats a rare, inherited eye condition
FOR SAFETY.” the urgency of parents whose child has a seri-
ous illness,” says High. “On the other hand, this
is a field where you cannot have two standards
caused by mutations to a gene called RPE65 for safety.”
that can cause blindness. New forms of gene-therapy delivery and Trial sponsors and regulatory agencies
Another was the announcement in August mechanisms of action sometimes do not also worry about how candidate products are
2018 that gene therapies no longer need to perform as expected when they enter clini- manufactured, and how the products might
be reviewed before clinical studies can begin cal studies. In September 2018, Sangamo be affected by changes in the manufacturing
by a US National Institutes of Health (NIH) Therapeutics, based in Richmond, California, process over time. Making gene therapies is
advisory committee on recombinant DNA reported the initial results of the first trial of a highly complex process using biological
that was created at the dawn of genetic medi- gene editing inside the body, for a therapy to materials, and extremely high quality must
cine. “There is no longer sufficient evidence to treat a rare metabolic disease called Hunter be assured at every step. Most academic labs
claim that the risks of gene therapy are entirely syndrome. The disease, which primarily affects and biotech startups lack the expertise and
unique and unpredictable — or that the field males, causes a host of serious symptoms, and the equipment to pull off this feat well enough
still requires special oversight that falls outside treatment currently requires weekly injections to produce commercial-grade therapies at
our existing framework for ensuring safety,” of enzymes. But the initial Sangamo trials failed a commercial scale. Few biomanufacturing
wrote Gottlieb and NIH director Francis to demonstrate clinical benefit, and they are facilities currently provide such services, and
Collins in a paper published earlier this year now continuing with higher doses. these operations are overloaded by the num-
(F. S. Collins & S. Gottlieb N. Engl. J. Med. 379, The regulatory agencies are seeking to provide ber of therapies now heading towards clinical
1393–1395; 2018). more guidance on such emerging gene-editing trials. The difficulties are compounded by the
Even so, such a new class of medicines still therapies. The EMA and the FDA are working need, as trials progress, to improve the manu-
poses serious risks. “It’s not that people say: together “to avoid digressions between the two facturing processes while keeping the product
‘Oh, it’s all safe, don’t worry’,” says Katherine of us”, says Hans-Georg Eichler, senior medical consistent enough to keep regulators happy.
High, a haematologist and president of Spark. officer at the EMA. “In gene therapy in general, “Manufacturing is something we will have
“It’s that now we really have some parameters we like to believe that we know what the major to think about differently, so we can get it right
inside which we can work.” risks are, but you can never know,” Eichler the first time,” says Peter Marks, director of
She points out, for example, that previous says. “Tomorrow, something totally new the FDA’s Center for Biologics Evaluation and
S19
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
Research in Silver Spring, Maryland, which committee members from various states meet find that reflected in the guidance documents
oversees gene therapies. to make decisions about marketing approval. that the FDA and the EMA provide.”
“Quite often people develop things on the At the FDA, reviewers within the appropriate Gene-therapy developers worry that the
lab bench at a very small scale, and they need division follow the drug candidate throughout agencies lack enough experts to deal with the
to scale up and scale out their thinking,” says its entire life cycle. incoming wave of trials for cell and gene thera-
Jacqueline Barry, chief clinical officer for the But the two agencies take similar data-driven pies, which the FDA estimates will reach 1,000
Cell and Gene Therapy Catapult, a UK gov- approaches to assessing drug safety and effi- a year by 2021. “They don’t have enough peo-
ernment commercial incubator. “We try to cacy, often actively working together in the ple to handle that kind of workload,” says High.
work with them very early on about moving process. Several times a year, for example, they “For the FDA, the issue is always around the
to a good manufacturing process and gather- hold teleconferences on gene therapies. “We all budget, and being able to have the appropriate
ing data that will support the evolution of the know there are so many uncertainties in this technology and people to deliver on their com-
product between clinical-trial phases without field, and so many new developments that we mitments,” says Peter Saltonstall, president of
having to go back and redo studies.” want to keep each other abreast of,” says Eichler. the National Organization for Rare Disorders
Gene therapies also require follow-up for based in Danbury, Connecticut.
patients that extends for years after prod- It is still early days for gene therapies, but
uct approval because the long-term effects
of these one-time treatments are simply “I DON’T SEE so far, developers generally give both agen-
cies high marks as partners. “I don’t see the
THE AGENCIES
not known. “Clinicians must come to grips agencies as a barrier at all,” says Byrne. “They
with that idea,” says Eichler. “As we treat, we have so many mechanisms for interacting with
must ascertain that the patient experience — sponsors now, and they’ve always approached
good or bad — must somehow be fed back to
decision-makers and contribute to long-term AS A BARRIER sponsors as collaborators in bringing these
agents forward.”
knowledge generation.”
SEEKING APPROVAL
AT ALL.” Eggimann agrees. “The regulators have been
very supportive of innovation and gene therapy
in general, and they are very eager to learn,” she
Europe and the United States have very different says. “Our challenge comes from the novelty of
legal and regulatory regimes for approving Both agencies released major updates to their the science, not so much from the regulatory
gene therapies. The main difference is that gene-therapy guidelines in 2018. The FDA, for aspects.”
the FDA oversees clinical trials, whereas the example, offered its first draft recommenda- Meanwhile, the therapies keep moving
EMA does not. To run a clinical trial in any tions by class of illness, starting with haemo- forward. Among them is AVXS-101, a gene
of the 28 members of the European Union, philia, retinal disorders and rare diseases. It therapy from AveXis based in Bannockburn,
“you have to get approval from a competent also added draft frameworks for certain man- Illinois. AVXS-101 has raised high hopes in
authority and from the ethics committee in ufacturing processes and requirements for early clinical trials for the treatment of spinal
that member state,” says Barry. You also have long-term patient follow-up. The EMA also muscular atrophy, that devastating neuro-
to get approval for using a genetically modified completely overhauled its frameworks for gene degenerative condition that affects children.
organism (GMO). However, “the clinical-trial therapies. For instance, it reworked its guidance In October 2018, AveXis applied to both the
directive and the GMO directive are trans- on the design, manufacture, characterization FDA and the EMA for marketing approval —
lated slightly differently in each country,” she and testing of delivery mechanisms. yet another bridge that gene therapy is crossing
points out. “As the field gains more and more on its journey from the lab to the clinic. ■
Moreover, participation in decisions is experience, the broad outlines of what needs
structured differently in Europe and the to be submitted to initiate clinical studies have Eric Bender is a science journalist based in
United States, says Eggimann. At the EMA, come more clearly into focus,” says High. “You Newton, Massachusetts.
S20
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
PERSPECTIVE
Access and affordability for all
The hope of gene therapy could be crushed by its financial burden unless
there are more rational ways of paying for it, says Michael Sherman.
G
ene therapy offers the possibility of a cure for previously extremely expensive treatments, is a good candidate for value-based
untreatable diseases. But although the science and technol- agreements. Take, for example, the high-cost biological drug eteplirsen,
ogy behind it are awe-inspiring, the costs can be daunting. which targets the gene responsible for Duchenne muscular dystrophy
Treatments are likely to have a price tag in the neighbourhood of (DMD). The FDA expedited approval of the drug in 2016 because
US$1 million or more — a cost that is ultimately borne by all individuals, DMD was a fatal, progressive disease with insufficient treatment
not just patients, through taxes and insurance premiums. options. Approval was granted despite the FDA’s advisory committee
In the United States, which lacks government-administered voting against it and despite slim evidence of efficacy — the pivotal trial,
provision of universal health care, there is a strong expectation that which enrolled just 12 boys, showed very small changes in the surrogate
health insurers will pay for therapies that have been approved by the measure used as an outcome.
US Food and Drug Administration (FDA), particularly if a treatment The agency’s decision sent shock waves through the US insurance
is the only effective one for a given malady. In cases in which the effi- industry and led to variability in coverage policies. Many companies
cacy data and value proposition are questionable, FDA approval can agreed to pay for the drug, which costs around $300,000 per year, but
create enormous pressure to provide coverage. others initially declined to do so.
Some stakeholders — including pharmaceutical companies and In this case, a value-based agreement could have set out a multi-
government policymakers — have been squeamish about introducing year payment model that would terminate if the effectiveness of the
measures of cost effectiveness into the decision- drug failed to persist over the long term. And
making process because of concerns that such because such a deal would enable broad access
an approach could lead to putting a price on life to the therapy, it would in turn generate robust
and, ultimately, the rationing of care. Unfortu-
nately, this has had an unintended consequence:
TREATMENTS real-world evidence of the treatment’s efficacy.
Such data could then be used to gain conven-
it has led to a system that has no mechanism for ARE LIKELY tional FDA approval. Sarepta Therapeutics in
imposing price ceilings. Many individuals in the
United States see substantial cost increases for
TO HAVE Cambridge, Massachusetts, the company that
developed eteplirsen, chose not to enter into
their medications year after year.
One possibility would be for the FDA to
A PRICE TAG value-based agreements for that drug, but it is
collaborating with a partner to develop a one-
consider a pathway in which it expedites approval IN THE time DMD gene therapy that is expected to be
for a treatment in the absence of sufficient high-
quality data, particularly for rare diseases that NEIGHBOURHOOD OF much more expensive. That therapy might pre-
sent an opportunity to enter into an innovative
have no effective treatment, in return for the
drug maker agreeing to a so-called value-based US$1 MILLION financing agreement to promote access.
Some pharmaceutical companies oppose
agreement that would tie reimbursement to the
success of the drug. When treatment works, the
manufacturer would receive full payment. When
OR MORE. value-based pricing, questioning whether the
approach maximizes shareholder value. It is fair
to acknowledge that any solution to improve
the patient shows a limited response to treat- access to health-care advances should provide a
ment, there would be a partial payment. And when the treatment fails reasonable return to the companies that develop such innovations. It is
altogether, no payment would be made. also appropriate to ask whether treatments for rare conditions should
I work for the health insurer Harvard Pilgrim Health Care in be priced higher to ensure that companies will pursue the development
Wellesley, Massachusetts, and in January my company entered into of drugs that will always have a limited market.
a value-based agreement with Spark Therapeutics in Philadelphia, Whether or not we choose to acknowledge it, there is a limit to the
Pennsylvania, for the gene therapy voretigene neparvovec portion of a country’s gross domestic product that can be spent on
(Luxturna), a treatment for a form of hereditary blindness. This agree- health care. To balance access and affordability over the long term and
ment is already driving considerable discussion between payers and ensure that our loved ones can receive the next generation of inno-
pharmaceutical companies that have upcoming gene therapies and vative therapies, payers, pharmaceutical companies and regulatory
other high-cost, innovative treatments. Other firms have forged simi- agencies need to collaborate in a way that benefits all stakeholders.
lar deals. For example, in 2016, the pharmaceutical company Novartis Value-based agreements from the past few years provide a model that
in Basel, Switzerland, signed a deal with several insurers, including could be applied to upcoming gene therapies and other high-cost,
Cigna in Bloomfield, Connecticut, and Harvard Pilgrim, for its com- innovative treatments. A spirit of collaboration among industry play-
bination drug sacubitril–valsartan, a treatment for heart failure. In ers could ensure that everyone who needs an innovative, expensive
the event that people receiving the drug fail to show a reduced rate of treatment can have access to it. ■
hospitalization for heart failure in clinical trials, the drug cost will be
reduced. Collaborative deals such as this give hope that stakeholders Michael Sherman is senior vice president and chief medical officer
will work together to ensure that all who might benefit have access to at Harvard Pilgrim Health Care in Wellesley, Massachusetts, and a
cutting-edge medical advances. faculty member at Harvard Medical School in Boston, Massachusetts.
Gene therapy, which offers the potential of extremely effective but e-mail: michael_sherman@harvardpilgrim.org
S21
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
www.nature.com/collections/gene-therapy-outlook
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
RECOMMENDED
By Andrea Gawrylewski
No Beast
So Fierce:
The Terrifying
True Story of the
Champawat Tiger,
the Deadliest Animal
in History
UĂD´yù`§y¨UàmyÎ
=¨¨D®$¹àà¹Āj÷ĈÀµÊu÷êεµË
523xþ¸§þxlî¸Uxxß`xîxßäj
UøîîxāßDßx§āDîîD`¦øD³äÍ
The Discrete Charm of the Machine: Good to Go: What the Athlete Nature’s Mutiny:
Why the World Became Digital in All of Us Can Learn from How the Little Ice Age of the Long
by Ken Steiglitz. the Strange Science of Recovery Seventeenth Century Transformed
Princeton University Press, 2019 ($27.95) by Christie Aschwanden. the West and Shaped the Present
W. W. Norton, 2018 ($27.95) by Philipp Blom. Liveright, 2019 ($27.95)
Digital technology has such
Dஹ¨m¹´®¹myà´¨yïDï After a long run, journalist For reasons still being ex-
it is hard to remember how Aschwanden went to relieve plored, Earth plunged into the
recently we lived without it. her sore legs with nitrogen gas. Little Ice Age from the late 16th
Computer scientist Steiglitz 3ïD´m´´D§ym´Dåïyy¨`D®- to the early 19th century. Across
examines the global transformation from analog ber and receiving a blast of frig- the Western world, failed har-
to digital and the ways it changed how we calcu- id air, she felt a rush of adrenaline. “I was ready to ÿyåïå¨ymï¹D®´yD´må¹`D¨ù´àyåïÎ7å´àåïÈyà-
late, communicate and entertain ourselves. He §`§å¹®yDååÎ Î Î jÛåyĀàïyåÎÚĀDå幨mÎÛ
ùïïy son accounts, history writer Blom shows how the
myå`àUyåïy´ùïåD´mU¹¨ïå¹ïD§´å¹®yï´ ïàùïjåy´må¹ùïjåïDï´¹å`y´ïåï`D´`¹´à® climatic upheaval helped to usher in economic and
analog, such as waves traveling through the air ïyUy´yïå¹ï姴m¹`àĂ¹ïyàDÈĂΨyï®y å`y´ï``D´yåÎ5y"ïï¨y`yyåÈùààymDà-
ïDï®D§yå¹ù´mjD´m`¹´ÿyàï´ïy®´ï¹ĈåD´m àD`yàD´m¹à®yà`à¹åå`¹ù´ïàĂå§yàjå`ĀD´my´ cultural innovations while causing considerable hu-
1s, all in witty and cogent language. In addition Èà¹ÿmyåD´D®ùå´D´myāDùåïÿyïD§ym¹Ā´ ®D´åùyà´D´mà¹Ā´´yÕùD¨ïĂιàyāD®È¨yj
to celebrating the gains of the digital revolution, ¹ïyày`¹ÿyàĂÈà¹mù`ïåD´mïày´måïDïï´yåå displaced by new farming practices, landless peas-
3ïy¨ïĆÕùyåï¹´åĀDïĀy®DĂDÿy¨¹åïÎ%¹ï´ enthusiasts have transformed into a multibillion- D´ïåymï¹`ïĂå¨ù®åjĀyàymåyDåyåÈàyDmyDå¨ĂÎ
ANUP SHAH Getty Images
that the human brain uses both analog and digital dollar industry, from sweating at infrared saunas to 5yU¹¹§ÿyå`¹´ïyāïï¹ïy`ùàày´ïù®D´màÿ-
®y`D´å®åjyDå§åjÚåïyàyå¹®yÜ®D`ÝïDï Ăm àDï´Āïåȹàïåmà´§åÎyà´m´åmyUù´§ en climate crisis, which is catalyzing similar shifts
remains hidden in the analog world, beyond the many ideas about what does help the body recov- and underscores that our choices dictate how glob-
àyD`¹ïymïD¨`¹®ÈùïyàÖÛ Clara Moskowitz er—and what does not. —Emiliano Rodríguez Mega al warming impacts human life.—Andrea Thompson
Zombie Baby occasionally need software updates. These introduce new features,
but they also often patch bugs and fix software vulnerabilities.
Alas, most devices vulnerable to Mirai were also shipped with no
ANTI GRAVITY
Steve Mirsky has been writing the Anti Gravity column since S A
a typical tectonic plate was about 36 inches from its current location. A A A S
He also hosts the IY_[dj_ÒY7c[h_YWdpodcast Science Talk.
What
the Deuce
A number of studies
about number two
By Steve Mirsky
F E B R UARY
köć¿´3`x³î
`xß`D³
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
РЕЛИЗ ПОДГОТОВИЛА ГРУППА "What's News" VK.COM/WSNWS
Soviet
GRAPHIC SCIENCE Union puts
Text by Mark Fischetti | Graphic by Jan Willem Tulp ïyàåïåDïy¨¨ïy
´ï¹åÈD`yÎRocket
U
launches globally
oins Soviet
since then:
Satellites and Debris Orbiting Earth Union and U S as
5,400
ach dot represents an o ect larger than centimeters a satellite proprietor
Satellites launched
1957
worldwide since
then: 8,650 Some
13
craft fall ac
1959 toward arth over
80 Total o ects trac ed time Satellites still
1961 ewly added y year in space: 4,700;
630 Decayed y year still functioning:
1963 1,800
1,180
1965
2,901
1967
1969
3,195 Space Junk
1971
4,040
4,477
Piles Up
EUROPEAN SPACE AGENCY www.esa.int; SPACE DEBRIS: THE ESA APPROACH. ESA BR-336. EUROPEAN SPACE AGENCY,
1973
4,943
Relentless accumulation
1975 threatens satellites and Earth
6,293